書籍詳細

I 総論

P.9 掲載の参考文献

• 1) Bresslau EL:The Mammary Apparatus of the Mammalia in the Light of Ontogenesis and Phylogenesis. 1920, Methuen, London

• 2) Sakakura T:New aspect of stroma-parenchyma relations in mammary gland differentiation. Int Rev Cytol 1991;125:165-202

• 3) Vonderhaar BK:Regulation of development of the normal mammary gland by hormones and growth factors. Breast Cancer:Cellular and Molecular Biology (Lippman ME, Dickson RB, eds). 1988;p251, Kluwer Academic Publishers, Boston, Dordrecht, London

• 4) Kratochwil K:In vitro analysis of the hormonal basis for the sexual dimorphism in the embryonic development of the mouse mammary gland. J Embryol Exp Morphol 1971;25:141-153

• 5) Kratochwil K, Schwartz P:Tissue interaction in androgen response of embryonic mammary rudiment of mouse:Identification of target time for testosterone. Proc Natl Acad Sci USA 1976;73:4041-4044

• 6) Huggins C, Grand L, Brilliantes FP:Mammary cancer induced by a single feeding of polynuclear hydrocarbons and its suppression. Nature 1961;189:204-207

• 7) Welsch WC:Host factors affecting the growth of carcinogen-induced rat mammary carcinomas:A review and tribute to Charles Brenton Huggins. Cancer Res 1985;45:3415-3443

• 8) Yoshida H, Yoshida A, Fukunishi R, et al:Biological characteristics and estrogen and progesterone receptors in mammary carcinoma induced in male Sprague-Dawley rats by a series of intragastric intubations of 7, 12-dimethylbenz (a)anthracene. Cancer Res 1982;42:2434-2439

• 9) Russo J, Tay LK, Russo IH:Differentiation of the mammary gland and susceptibility to carcinogenesis:A review. Breast Cancer Res Treat 1982;2:5-73

P.15 掲載の参考文献

• 1) Kollmann J:Handatlas der Entwicklungsgeschichte des Menschen, Zweiter Teil. Integmentum commune et Organa sensuum. 1907, Gustav Fischer, Jena

• 2) Merkel F:J Henle's Grundriss der Anatomie des Menschen, Atlas, 4th ed. 1901;p247, Friedrich Vieweg und Sohn, Braunschweig

• 3) Iwai T:Astatistical study on the polymastia of the Japanese. Lancet 1907;ii:753-759

• 4) 高橋喜嗣, 大熊守也, 手塚 正:副乳. 皮膚1980;22:189-190

• 5) Patten BM:Human Embryology, 2nd ed. 1953;p242, McGraw-Hill, New York

• 6) Arey LB:Developmental anatomy. A Textbook and Laboratory Manual of Embryology, 7th ed. 1965;pp449-453, WB Saunders, Philadelphia, London

• 7) Lazard D, Sastre X, Frid MG, et al:Expression of smooth muscle-specific proteins in myoepithelium and stromal my ofibroblasts of normal and malignant breast tissue. Proc Natl Acad Sci USA 1993;90:999-1003

• 8) Viale G, Gambacorta M, Coggi G, et al:Glial fibrillary acidic protein immunoreactivity in normal and diseased human breast. Virchows Arch-A Pathol Anat Histopathol 1991;418:339-348

• 9) Tobon H, Salazar H:Ultrastructure of the human mammary gland. I. Development of the fetal gland throughout gestation. J Clin Endocrinol Metab 1974;39:443-456

• 10) Dabelow A:Die Milchdruse. Handbuch der mikroskopischen Anatomie des Menschen(von Wilhelm M, Bargmann W, eds), Band 3, Teil 3. 1957;pp277-488, Springer-Verlag, Berlin

• 11) Nagel A:Das elastisch-muskulose System der Brustwarze. Morph Jahrb 1942;87:216-253

• 12) Anbazhagan R, Bartek J, Monaghan P, et al:Growth and development of the human infant breast. Am J Anat 1991;192:407-417

• 13) Knight CH, Peaker M:Development of the mammary gland. J Reprod Fertil 1982;65:521-536

P.27 掲載の参考文献

• 1) Bloom W, Fawcett DW:乳腺. ブルーム・フォーセット組織学(II), 第11版(山田英智, 市川 厚, 黒住一昌, 監訳). 1991;pp1019-1031, 廣川書店, 東京

• 2) 野村雍夫:構造と機能. 新外科学大系18, 乳房の外科. 1988;pp3-28, 中山書店, 東京

• 3) Drife JD:Evolution, menstruation, and breast cancer. Commentaries on Research in Breast Disease (Bulbrook RD, Taylor DJ, eds), vol 1. 1979;pp2-23, Alan R Liss, New York

• 4) 溝口史郎:皮膚および皮膚付属器. 図説組織学, 第2版. 1990;pp220-224, 金原出版, 東京

• 5) 小川和朗, 溝口史郎:乳腺. 皮膚付属器官, 組織学. 1987;pp331-335, 文光堂, 東京

• 6) 藤森正雄, 馬場憲臣:解剖. 現代外科学大系29, 胸部損傷, 胸壁, 乳房. 1968;pp109-113, 中山書店, 東京

• 7) 佐藤達夫:乳房の解剖と生理. 乳腺疾患, 第2版(泉雄 勝, 妹尾亘明, 編). 1993;pp 1-3, 金原出版, 東京

• 8) Vorherr H:Morphology, physiology, and lactation. The Breast. 1974, Academic Press, New York

• 9) Tanner JM:Growth and endocrinology of the adolescent. Endocrine and Genetic Diseases of Childhood 19 (Gardner LI, ed). 1962;p28, Blackwell Scientific Publication, Oxford

• 10) 矢内原巧, 河合清文, 石塚雄作, ほか:Reproductive organとしての乳房管理. 発達内分泌学と乳房思春期における変化. NEW MOOK産婦人科, 1. 乳房管理(荒井 清, 編). 1991; pp10-17, 金原出版, 東京

• 11) 玉田太朗:思春期の内分泌. 日本内分泌学会雑誌1978;54:1331

• 12) 矢内原巧, 大野秀夫, 東郷実昌, ほか:思春期の内分泌, 思春期と女性ホルモン. 小児科 MOOK 34, 思春期(中村 孝, 編). 1984;pp91-103, 金原出版, 東京

• 13) Hopper BR, Yen SSC:Circulating concentrations of dehydroepiandrosterone and dehydroepiandrosterone sulfate during Puberty. J Clin Endocrinol Metab 1975;40:458-461

• 14) Marvais JP, Kutten F:Les mastopathies benignes. Nouv Presse Med 1974;3:993-994

• 15) Jacquemier JD, Hassoun J, Torrente M, et al:Distribution of oestrogen and progesterone receptors in healthy tissue adjacent to breast lesions at various stage:Immunohistochemical study of 107 cases. Breast Cancer Res Treat 1990;15:109-117

• 16) 小林俊三, 岩瀬弘敬:乳房の解剖と生理. 乳腺疾患, 第2版(泉雄 勝, 妹尾亘明, 編). 1993;pp36-45, 金原出版, 東京

• 17) 榎本耕治:機構および機能異常. 新外科学大系18, 乳房の外科. 1988;pp297-316, 中山書店, 東京

• 18) Thorneycroft IH:The relation of serum 17-hydroxyprogesterone and estradiol-17β levels during the human menstrual cycle. Am J Obstet Gynecol 1971;111:947-951

• 19) Haagensen CD:Disease of the Breast. 1971;pp1-67, WB Saunders, Philadelphia

P.40 掲載の参考文献

• 1) Houdebine LM, Djiane J, Dusanter-Fourt I, et al:Hormonal action controlling mammary activity. J Dairy Sci 1985;68:489-500

• 2) Kelly PA, Djiane J, Postel-Vinay MC, et al:The prolactin/growth hormone receptor family. Endocr Rev 1991;12:235-251

• 3) Campbell GS, Argetsinger LS, Ihle JN, et al:Activation of JAK2 tyrosine kinase by prolactin receptors in Nb2 cells and mouse mammary gland explants. Proc Natl Acad Sci USA 1994;91:5232-5236

• 4) Delouis C, Djiane J, Houdebine LM, et al:Relation between hormones and mammary gland function. J Diary Sci 1980;63:1492-1513

• 5) Servely JL, N'Guema Emane M, Houdebine LM, et al:Comparative measurement of the lactogenic activity of ovine placental lactogen in rabbit and ewe mammary gland. Gen Comp Endocrinol 1983;51:255-262

• 6) Akers RM, Keys JE:Effects of suckling intensity on human growth hormone binding, biochemical composition and histological characteristics of ovine mammary glands. Domest Anim Endocrinol 1985;2:159-172

• 7) Ronge H, Blum JW:Insulin-like growth factor I responses to growth hormone in dry and lactating dairy cows. J Anim Physiol Anim Nutr 1989;62:280-288

• 8) Hadsell DL, Campbell PG, Baumrucker CR:Characterization of the change in type I and II insulin-like growth factor receptors of bovine mammary tissue during the pre-and postpartum periods. Endocrinology 1990;126:637-643

• 9) McGrath MF, Collier RJ, Clemmons DR, et al:The direct effect of insulin-like growth factors (IGFs) on normal bovine mammary cell proliferation and production of 1GF binding proteins:An in vitro study. Endocrinology 1991;129:671-67810)

• 10) Plaut K, Ikeda M, Vonderhaar BK:Role of growth hormone and insulin-like growth factor-I in mammary development. Endocrinology 1993;133:1843-1848

• 11) Nagamatsu Y, Oka T:The differential actions of cortisol on the synthesis and turnover of α-lactalbumin and casein and on accumulation of their mRNA in mouse mammary gland in organ culture. Biochem J 1983;212:507-515

• 12) Chomczynski P, Zwierchowski L:Mammary glucocorticoid receptor ofmice in pregnancy and in lactation. Biochem J 1976;158:481-483

• 13) Sankaran L, Qasba P, Topper YJ:Effects of estrogen-depletion on rat casein gene expression. Biochem Biophys Res Commun 1984;125:682-689

• 14) Goodman GT, Akers RM, Friderici KH, et al:Hormonal regulation of α-lactalbumin secretion from bovine mammary tissue cultured in vitro. Endocrinology 1983;112:1324-1330

• 15) Hsueh AJW, Peck EJ, Clark JH:Oestrogen receptors in the mammary gland of the lactating rat. J Endocrinol 1983;58:503-511

• 16) Capuco AV, Feldhoff PA, Akers RM, et al:Progestin binding in mammary tissue of prepartum, nonlactating and postpartum, lactating cows. Steroids 1982;40:503-517

• 17) Ganguly R, Majumder PK, Ganguly N, et al:The mechanism of progesterone-glucocorticoid interaction in regulation of casein gene expression. J Biol Chem 1982;257:2182-2187

• 18) Shyamala G, McBlain WA:Distinction between progestin-and glucocorticoid-binding sites in mammary glands:Apparent lack of cytoplasmic progesterone receptors in lactating mammary 91ands. Biochem J 1979;178:345-352

• 19) Tucker HA:Endocrinology of lactation. Semin Perinatol 1979;3:199-233

• 20) Taketani Y, Oka T:Epidermal growth factor stimulates cell proliferation and inhibits functional differentiation of mouse mammary epithelial cells in culture. Endocrinology 1983;113:871-877

• 21) Ethier SP, Kudla A, Cundifr KC:Influence of hormone and growth factor interactions on the proliferative potential of normal rat mammary epithelial cells in vitro. J Cell Physiol 1987;132:161-167

• 22) Okamoto S, Oka T:Evidence for physiological function of epidermal growth factor:Pregestational sialadenectomy of mice decreases milk production and increases offspring mortality during lactational period. Proc Natl Acad Sci USA 1984;81:6059-6063

• 23) Coleman S, Daniel CW:Inhibition of mouse mammary ductal morphogenesis and down regulation of the EGF receptor by epidermal growth factor. Dev Biol 1990;137:425-433

• 24) Haslam SZ, Nummy KA:The ontogeny and cellular distribution ofestrogen receptors in normal mouse mammary gland. J Steroid Biochem Mol Biol 1992;42:589-595

• 25) Liscia DS, Merlo G, Fortunato C, et al:Transforming growth factor-α messenger RNA localization in the developing adult rat and human mammary gland by in situ hybridization. Dev Biol 1990;140:123-131

• 26) Ethier SP, Van de Velde RM:Secretion of a TGF-β-like growth inhibitor by normal rat mammary epithelial cells in vitro. J Cell Physiol 1990;142:15-20

• 27) Daniel CW, Silberstein GB, Van Horn K, et al:TGF-β1-induced inhibition of mouse mammary ductal growth:Developmental specificity and characterization. Dev, Biol 1989;135:20-30

• 28) Silberstein GB, Flanders KC, Roberts AB, et al:Regulation of mammary morphogenesis-evidence for extracellular matrix-mediated inhibition of ductal budding by transforming growth factor-β1. Dev Biol 1992;152:354-362

• 29) Barrett-Lee P, Travers M, Luqmani Y, et al:Transcripts for transforming growth factors in human breast cancer:Clinical correlates. Br J Cancer 1990;61:612-617

• 30) Yee D, Paik S, Lebovic G, et al:Analysis of insulin-like growth factor I gene expression in malignancy:Evidence for a paracrine role in human breast cancer. Mol Endocrinol 1989;3:509-517

• 31) Kleinberg DL, Ruan W, Catanese V, et al:Nonlactogenic effects of growth hormone on growth and insulin-like growth factor-I messenger ribonucleic acid of rat mammary gland. Endocrinology 1990;126:3274-3276

• 32) Levay-Young BK, Imagawa W, Wallace DR, et al:Basic fibroblast growth factor stimulates the growth and inhibits casein accumulation in mouse mammary epithelial cells in vitro. Mol Cell Endocrinol 1989;62:327-336

• 33) Gomm JJ, Smith J, Ryall GK, et al:Localization of basic fibroblast growth factor and transforming growth factor β1 in the human mammary gland. Cancer Res 1991;51:4685-4692

• 34) Nishikawa S, Moore RC, Nonomura N, et al:Progesterone and EGF inhibit mouse mammary gland prolactin receptor and β-casein gene expression. Am J Physiol 1994;267:C1467-C1472

• 35) Lee CS, Oka T:Progesterone regulation of pregnancy-specific transcription repressor to β-casein gene promoter in mouse mammary gland. Endocrinology 1992;131:2257-2262

• 36) Hinuma S, Habata Y, Fujii R, et al:A prolactin-releasing peptide in the brain. Nature 1998;393:272-276

• 37) Lyons WR, Li CH, Rice-Wray AN:Mammotrophic effects of human hypophysial growth hormone preparations in animals and man. Exerpta Med Int Cong Ser 1968;158:349-363

• 38) Dahl GE, Chapin LT, Allen MS, et al:Comparison of somatotropin and growth hormone releasing factor on milk yield, serum hormones, and energy status. J Dairy Sci 1991;74:3421-3428

• 39) Keenan BS, Buzek SW, Garza C:Cortisol and its possible role in regulation of sodium and potassium in human milk. Am J Physiol 1983;244:E253-E261

• 40) Quirk SJ, Gannell JE, Funder JW:Aldosterone-binding sites in pregnant and lactating rat mammary gland. Endocrinology 1983;113:1812-1817

• 41) Ziska SE, Bhattacharjee M, Herber RL, et al:Thyroid hormone regulation of α-lactalbumin:Differential glycosylation and messenger ribonucleic acid synthesis in mouse mammary glands. Endocrinology 1988;123:2242-2248

• 42) Tyson JE, Peres A, Zanartu J:Human lactational response to oral thyrotropin-releasing hormone. J Endocrinol Metab 976;43:760-768

• 43) Riis PM, Madsen A:Thyroxine concentrations and secretion rates in relation to pregnancy, lactation and energy balance in goats. J Endocrinol 1985;107:421-427

• 44) Oberkotter LV, Farmer LC, Farber M:Thyroid hormone-binding inhibitor in normal, pregnant, and lactating rat and postmenopausal human breast tissue. Endocrinology 1985;117:511-514

• 45) Fenton SE, Sheffield LG:Lactogenic hormones increase epidermal growth factor messenger RNA content of mouse mammary glands. Biochem Biophys Res Commun 1991;181:1063-1069

• 46) Izuno Y, Fujita N, Senzaki H, et al:Immunohistochemical demonstration of epidermal growth factor in lactating mammary glands in sialoadenectomized mice. Acta Histochem Cytochem 1991;24:295-300

• 47) Bissell MJ, Hall HG:Form and function in the mammary gland. The role of the extracellular matrix. The Mammary Gland:Development, Regulation, and Function (Neville MC, Daniel CW, eds). 1987;pp97-146, Plenum Press, New York

• 48) Bondy CA, Gainer H, Russell JT:Effects of stimulus frequency and potassium channel blockage on the secretion of vasopressin and oxytocin from the neurohypophysis. Neuroendocrinology 1987;46:258-267

• 49) Parker SL, Armstrong WE, Sladek CD, et al:Prolactin stimulates the release of oxytocin in lactating rats:Evidence for a physiological role via an action at the neural lobe. Neuroendocronology 1991;53:503-510

• 50) Quarrie LH, Addey CVP, wilde CJ:Apoptosis in lactating and involuting mouse mammary tissue demonstrated by nick-end DNA labelling. Cell Tissue Res 1995;281:413-419

• 51) Feng Z, Marti A, Jehn B, et al:Glucocorticoid and progesterone inhibit involution and programmed cell death in the mouse mammary gland. J Cell Biol 1995;131:1095-1103

• 52) Neuenschwander S, Schwartz A, Wood TL, et al:Involution of the lactating mammary gland is inhibited by the IGF system in a transgenic mouse model. J Clin Invest 1996;97:2225-2232

• 53) Strange R, Li F, Saurer S, et al:Apoptotic cell death and tissue remodelling during mouse mammary gland involution. Development 1992;115:49-58

• 54) Lu PJ, Lu QL, Rughetti A, et al:bcl-2 overexpression inhibits cell death and promotes the morphogenesis, but not tumorigenesis of human mammary epithelial cells. J Cell Biol 1995;129:1363-1378
  pubmed

P.49 掲載の参考文献

• 1) 日本乳癌学会(編):臨床・病理乳癌取扱い規約, 第13版. 1998;pp19-34, 金原出版, 東京

• 2) WHO:Histological Typing of Breast Tumours, 2nd ed (International Histological Classification of Tumours No 2), 1981, World Health Organization, Geneva

• 3) 坂元吾偉:良性上皮性腫瘍. 乳腺腫瘍病理アトラス, 改訂第2版. 1995;pp10-31, 篠原出版, 東京

• 4) 今村 洋, 坂元吾偉, 秋山 太, ほか:非浸潤性乳管癌の自然史. 乳癌の臨床1993;8:123-128

• 5) 向山雄人, 小川一誠, 堀越 昇, ほか:再発・進行乳癌剖検例100例の転移動態. 乳癌の臨床 1989;4:121-126

• 6) 坂元吾偉:結合織性および上皮性混合腫瘍. 乳腺腫瘍病理アトラス, 改訂第2版. 1995;pp87-98, 篠原出版, 東京

• 7) 日馬幹弘:乳腺症の概念. 乳腺症の臨床(坂元吾偉, 監). 1997;pp3-4, 篠原出版, 東京

P.56 掲載の参考文献

• 1) Green S, Walter P, Kumar V, et al:Human oestrogen receptor cDNA, sequence, expression and homology to v-erb-A. Nature 1986;320:134-139

• 2) 佐藤文三:乳癌のホルモン依存性増殖機構. 内分泌外科1995;12:313-319

• 3) Mendel DB, Bodwell JE, Gametchu B, et al:Molybdate-stabilized nonactivated glucocorticoid-receptor complexes contain a 90-kDa non-steroid-binding phosphoprotein that is lost on activation. J Biol Chem 1986;261:3758-3763

• 4) 佐藤文三:内分泌疾患の遺伝子学. 臨床遺伝子学'92(最新医学増刊号). 1992;pp1748-1771, 最新医学社, 大阪

• 5) Halachmi S, Marden E, Martin G, et al:Estrogen receptor-associated proteins:Possible mediators of hormone-induced transcription. Science 1994;264:1455-1458

• 6) Horwitz KB, Jackson TA, Bain DL, et al:Nuclear receptor coactivators and corepressor. Mol Endocrinol 1996;10:1167-1177

• 7) Smith CL, Nawaz Z, O'Malley BW:Coactivator and corepressor regulation of the agonist/ antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol 1997;11:657-666

• 8) Onate SA, Tsai SY, Tsai M-J, et al:Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 1995;270:1354-1357

• 9) Kamei Y, Xu L, Heinzel T, et al:ACBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 1996;85:403-414

• 10) Torchia J, Rose DW, Inostroza J, et al:The transcriptional co-activator p/CIP binds CBP and mediates nuclear receptor function. Nature 1997;387:677-684

• 11) Struhl K, Moqtaderi Z:The TAFs in the HAT, Cell 1998;94:1-4

• 12) Chrivia JC, Kwob RPS, Lamb N, et al:Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature 1993;365:855-859

• 13) Umayahara Y, Kawamori R, Watada H, et al:Estrogen regulation of the insulin-like growth factor 1 gene transcription involves an AP-l enhancer. J Biol Chem 1994;269:16433-16442

• 14) Webb P, Lopez GN, Uht RM, et al:Tamoxifen activation of the estrogen receptor/AP-1 pathway:Potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol 1995;9:443-456

• 15) Kuiper GGJM, Enmark E, Pelto-Huikko M, et al:Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc Natl Acad Sci 1996;93:5925-5930

• 16) Dotzlaw H, Leygue E, Watson PH, et al:Expression of estrogen receptor-beta in human breast tumors. J Clin Endocrinol Metab 1996;82:2371-2374

• 17) Feigelson HS, Shames LS, Pike MC, et al:Cytochrome P450 17α gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res 1998;58:585-587

• 18) Hilakivi-Clarke L, Clarke L, Onoj afe I, et al:A maternal diet high in n-6 polyunsaturated fats alters mammary gland development, puberty onset, and breast cancer risk among female rat offspring. Proc Natl Acad Sci 1997;94:9372-9377

• 19) Fotsis T, Zhang Y, Pepper MS, et al:The estrogenous metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumor growth. Nature 1994;368:237-239

• 20) Fishman J, Osborne MP, Telang NT:The role of estrogen in mammary carcinogenesis. Ann NY Acad Sci 1995;768:91--100

• 21) Koos RD, Banks PK, Inkster SE, et al:Detection of aromatase and keratinocyte growth factor expression in breast tumors using reverse transcription-polymerase reaction. J Steroid Biochem Mol Biol 1993;45:217-225

• 22) van Landeghen AAJ, Poortman J, Nabuurs MJ, et al:Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res 1985;45:2900-2906

• 23) Jordan VC:Overview from the international conference on long-term tamoxifen therapy for breast cancer. J Natl Cancer Inst 1992;84:231-234

• 24) Yang NN, Venugopalan M, Hardikar S, et al:Identification of an estrogen response element activated by metabolites of 17β estradiol and raloxifene. Science 1996;273:1222-1225

• 25) Wakeling AE, Dukes M, Bowler J:A potent specific pure antiestrogen with clinical potential. Cancer Res 1991;51:3867-3873

• 26) Bartkova J, Lukas J, Muller H, et al:Cyclin D1 protein expression and function in human breast cancer. Int J Cancer 1994;57:353-361

• 27) Renate M, Zwijsen L, Weientjens E, et al:CDK-independent activation of estrogen receptor by cyclin D1. Cell 1997;88;405-415

• 28) Pacilio C, Germano D, Addeo R, et al:Constitutive overexpression of cyclin D1 does not prevent inhibition of hormone-responsive human breast cancer cell growth by antiestrogens. Cancer Res 1998;58:871-876
  pubmed

• 29) Lippman ME, Dickson RB:Mechanism of growth control in normal and malignant breast epithelium. Recent Prog Horm Res 1989;45:383-440

• 30) Koga M, Kasayama S, Matsumoto K, et al:Minireview:Molecular mechanism of androgen-dependent growth in transformed cells:Pathway from basic science to clinical application. J Steroid Biochem Mol Biol 1995;54:1-6

• 31) Wooster R, Mangion J, Eeles R, et al:A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome. Nat Genet 1992;2:132-134

• 32) Saito H, Oka T:Hormonally regulated double-and single-stranded DNA-binding complexes involved in mouse β-Casein gene transcription. J Biol Chem 1996;271:8911-8918

• 33) Boutin JM, Jolicocur C, Okamura H, et al:Cloning and expression of the rat prolactin receptor, a member of the growth hormone/prolactin receptor family. Cell 1988;53:69-77

• 34) 佐藤文三:FGFレセプター1の構造・機能と発現制御. Molecular Medicine 1993;30:978-985

• 35) Pawson T, Schlessinger J:SH2 and SH3 domains. Current Biol 1993;3:434-442

• 36) Kato S, Endoh H, Masuhiro Y, et al:Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995;270:1491-1494

II 妊娠, 分娩, 産褥と乳房

P.65 掲載の参考文献

• 1) 福田雅文:「母子同室」と「母乳」と「授乳」. 周産期医学1996;26:521-524

• 2) 喜多悦子, 若杉なおみ, 青山温子, ほか:世界の母乳栄養の状況. 周産期医学1996;26:465-470

• 3) 小林 登:母子相互作用と母乳哺育. 臨床婦人科産科1981;35:798-801

• 4) 山内逸朗:早期授乳と母乳確立. 周産期医学1990;20:309-312

• 5) Klaus MH, Jerauld R, Kreger NC, et al:Maternal attachment:Importance of the first postpartum days. N Engl J Med 1972;289:460-463

• 6) 白岩義夫:母子相互作用に必要な新生児の応答性-認知能力と応答能力. Neonatal Care 1998;11:17-22

• 7) 山内芳忠:早期授乳と母児の絆. 臨床婦人科産科1996;50:882-884

• 8) Klaus MH, Kennel JH:Parent-Infant Bonding, 2nd ed. 1982, CV Mosby, New York (竹内 徹, 柏木哲夫, 横尾京子(訳):親と子のきずな. 1985, 医学書院, 東京)

• 9) Klopfer P:Mother love:What turns it on? Am Sci 1971;59:404-407

• 10) Salariya EM, Easton PM, Cater JI:Duration of breast-feeding after early initiation and frequent feeding. Lancet 1978;ii:1141-1143

• 11) Righard L, Alade MO:Effect of delivery room routines on success of first breast-feed. Lancet 1990;336:1105-1107

• 12) Roberton NRC:A Manual of Normal Neonatal Care, 2nd ed. 1996;pp121-123, Oxford University Press, New York

• 13) Riordan J, Auerbach KG:Breastfeeding and Human Lactation. 1993, Jones and Bartlett Publishers, Boston

• 14) Hamosh M, Bitman J, Wood L, et al:Lipids in milk and the first steps in their digestion. Pediatrics 1985;75:146-150

• 15) Luukkainen P, Salo MK, Nikkari T:Changes in the fatty acid composition of preterm and term human milk from 1 week to 6 months of lactation. J Pediatr Gastroenterol Nutr 1994;18:355-360

• 16) 守田哲朗:母乳の栄養学的特徴. 臨床新生児栄養学. 1996;pp132-138, 金原出版, 東京

• 17) 吉永宗義:母乳育児とビタミンK. 周産期医学1996;26:559-562

• 18) Lewis-Jones DI, Lewis-Jones MS, Connolly RC, et al:Sequential changes in the antimicrobial protein concentrations in human milk during lactation and its relevance to banked human milk. Pediatr Res 1985;19:561-565

• 19) 木下 洋:母乳の感染防御因子. 周産期医学1996;26:491-494

• 20) Goldman AS, Thorpe LW, Goldblum RM, et al:Anti-inflammatory properties of human milk, Acta Paediatr Scand 1986;75:689-695

• 21) Goldman AS, Chheda S, Garofalo R:Evolution of immunologic functions of the mammary gland and the postnatal development of immunity. , Pediatr Res 1998;43:155-162

• 22) Anderson B, Porras O, Hanson LA, et al:Inhibition of attachment of Streptococcus pneumoniae and Haemophilus influenzae by human milk and receptor oligosaccharides. J Infect Dis 1986;153:232-237

• 23) Rueda R, Sabatel JL, Maldonado J, et al:Addition of gangliosides to an adapted milk formula modifies levels of fecal Escherichia coli in preterm newborn infants. J Pediatr 1998;133:90-94

• 24) Galofalo R, Goldman AS:Cytokines, and colony-stimulating factors in human milk:The 1997 update. J Biol Neonate 1997;74:134-142

• 25) Ellis LA, Mastro AM, Picciano MF:Do milk-borne cytokines and hormones influence neonatal immune cell function? J Nutr 1997;127:985S-988S

• 26) Skansen-Saphir U, Lindfors A, Andersson U:Cytokine production in mononuclear cells of human milk studied at the single-cell level. Pediatr Res 1993;34:213-216

• 27) Garofalo R, Chheda S, Mei F, et al:Interleukin-10 in human milk. Pediatr Res 1995;37:444-449

• 28) Carver JD, Pimentel B, Cox WI, et al:Dietary nucleotide effects upon immune function in infants. Pediatrics 1991;88:359-363

• 29) Carpenter G:Epidermal growth factor is a major growth-promoting agent in human milk. Science 1980;210:198-199

• 30) Diaz-Gomez NM, Domenech E, Barroso F:Breast-feeding and growth factors in preterm newborn in fants. J Pediatr Gastroenterol Nutr 1997;24:322-327

• 31) Koldovsky O:Hormonally active peptides in human milk. Acta Paediatr Suppl 1994;402:89-93

• 32) 長山淳哉:しのびよるダイオキシン汚染. 1994, 講談社, 東京

• 33) 橋本武夫, 本郷寛子:母乳とダイオキシン. 助産婦雑誌1997;51:1050-1054

• 34) Koopman-Esseboom C, Weisglas-Kuperus N, de Ridder MA, et al:Effect of polychlorinated biphenyl/dioxin exposure and feeding type on infants' mental and psychomotor development. Pediatrics 1996:97;700-706

P.74 掲載の参考文献

• 1) 神津トミ子, 難波美奈:用手乳管開通操作(乳管開通法). 助産婦雑誌1996;50:470-471

• 2) Neifert M, Lawrence R, Seacat J, et al:Nipple confusion:Toward a formal definition. J Pediatr 1995;126:S125-S129

• 3) 山内芳忠, 中山真由美:乳児期早期の栄養指導について. 母子にすすめる栄養指導(一條元彦, 編著). 1997;pp249-252, メディカ出版, 大阪

• 4) La Leche League International:Normal growth patterns during the baby's first year. The Breastfeeding Answer Book. 1997;pp114-116, La Leche League International, Illinois

• 5) Cohen RJ, Brown KH, Canahuati J, et al:Determinants of growth from birth to 12 months among breast-fed Honduran infants in relation to age of introduction of complementary foods. Pediatrics 1995;96:504-510

• 6) 中山真由美:乳房のマイナートラブル. 臨床婦人科産科1996;50:910-912

• 7) Hoffman JB:A suggested treatment for inverted nipples. Am J Obstet Gynecol 1953;66:346-348

• 8) 神津トミ子, 松重泰代, 成広豊子, ほか:乳房の手入れ. 母親学級・両親学級指導マニュアル. ペリネイタルケア(夏季増刊)1996;185:182-189

• 9) La Leche League International:Sore nipples. The Breastfeeding Answer Book. 1997;pp388-393, La Leche League International, Illinois

• 10) Riordan J(竹内 徹, ほか訳):母乳哺育の実際. 1988;pp145-148, 医学書院, 東京

• 11) American Academy of Pediatrics, Committee on Drugs:The transfer of drugs and other chemicals into human milk. Pediatrics 1994;93:137-150

• 12) Briggs GG, Freeman RK, Yaffe SJ:Drugs in Pregnancy and Lactation. 1994, Williams & Wilkins, London

• 13) 南部春生, 太田八千雄, 服部哲夫, ほか:離乳と断乳「自然卒乳の提唱」. 周産期医学1996;26:525-530

• 14) American Academy of Pediatrics, Work Group on Breastfeeding:Breastfeeding and use of human milk. Pediatrics 1997;100:1035-1039

P.80 掲載の参考文献

• 1) Heywang-Kobrunner SH, Schreer I, Dershaw DD:Diagnostic Breast Imaging. 1997;p123, Thieme, Stuttgart, New York

• 2) 坂元吾偉:乳腺腫瘍病理アトラス, 改訂第2版. 1995, 篠原出版, 東京

• 3) Longacre TA, Bartow SA:A correlative morphologic study of human breast and endometrium in the menstrual cycle. Am J Surg Pathol 1986;10:382-393

• 4) Ferguson DJ P, Anderson TJ:Morphological evaluation of cell turnover in relation to the menstrual cycle in the "resting" human breast. Br J Cancer 1981;44:177-181

• 5) 土橋一慶:乳房の異常. 新女性医学大系4, 女性の症候学. 1998;pp83-97, 中山書店, 東京

• 6) Rosen PP:Carcinoma in ectopic breast tissue. Rosen's Breast Pathology. 1997;pp584-586, Lippincott Raven, Philadelphia

• 7) Morimoto T, Sasa M, Yamaguchi T, et al:Effectiveness of mammographic screening for breast cancer in women aged over 50 years in Japan. Jpn J Cancer Res 1997;88:778-784

• 8) White E, Velentgas P, Mandelson MT, et al:Variation in mammographic breast density by time in menstrual cycle among women aged 40-49 years. J Natl Cancer Inst 1998;90:906-910

• 9) 山口和子, 土橋一慶:妊娠時の乳房検診方法. 産婦人科の世界1997;49:178-182

P.85 掲載の参考文献

• 1) Thomsen AC, Hansen KB, Moller BR:Leukocyte counts and microbiologic cultivation in the diagnosis of puerperal mastitis. Am J Obstet Gynecol 1983;146:938-941

• 2) Niebyl JR, Spence MR, Parmley TH:Sporadic (nonepidemic) puerperal mastitis. J Reprod Med 1978;20197-100

• 3) Lee BJ, Tannebaum NE:Inflammatory carcinoma of the breast. Surg Gynecol Obstet 1924;39:580-595

• 4) Reddin A, McCrea ES, Keramati B:Inflammatory breast disease:Mammographic spectrum. South Med J 1988;81:981-984

• 5) Benson EA:Management of breast abscesses. World J Surg 1989;13:753-756

• 6) Scholefield JH, Duncan JL, Rogers K:Review of a hospital experience of breast abscesses. Br J Surg 1987;74:469-470

• 7) O'Hare RJ, Dexter SPL, Fox JN:Conservative management of infective mastitis and breast abscesses after ultrasonographic assessment. Br J Surg 1996;83:1413-1414

P.92 掲載の参考文献

• 1) 和田富雄:線維腺腫と葉状腫瘍. 乳腺疾患, 改訂第2版(泉雄 勝, ほか編). 1993;pp269-277, 金原出版, 東京

• 2) Fechner RE:Fibroadenoma and related lesions. Diagnostic Histopathology of the Breast (Page DL, ed). 1987;pp72-88, Churchill Livingstone, Edinburgh

• 3) Pike AM:Juvenile adenofibroma:A clinicopathologic study. Am J Surg Pathol 1985;9:730-736

• 4) 世界保健機関(WHO):乳腺腫瘍の組織分類. 癌の臨床1982;28:1207-1224

• 5) Haagensen CD:Disease of the Breast, 3rd ed. 1986;pp284-312, WB Saunders, Philadelphia

• 6) 第36回乳癌研究会:アンケートのまとめ. 日本癌治療学会誌1983;18:1201-1255

• 7) 大内憲明, 阿部力哉:乳管内乳頭腫からの癌発生に関する研究. 日本外科学会雑誌1984;85:175-181

• 8) 阿部力哉:その他の良性腫瘍および腫瘍様病変. 乳腺疾患, 改訂第2版(泉雄 勝, ほか編). 1993;pp287-294, 金原出版, 東京

• 9) Hoover HC Jr:Breast cancer during pregnancy and lactation. Surg Clin North Am 1990;70:1151-1163

• 10) 小山博記, 和田富雄:乳癌と妊娠. 外科1984;46:229-231

• 11) 下妻晃二郎, 冨永健, 林和雄, ほか:妊娠, 授乳期の乳癌の検討. 日本癌治療学会誌1991;26:929-934

• 12) King RM, Welch JS, Martin JK, et al:Carcinoma of the breast associated with pregnancy. Surg Gynecol Obstet 1990;160:228-232

• 13) 野村雍夫:妊娠期に発見された乳癌. 外科1984;46:228-231

• 14) 石田常博, 横江隆夫, 霞富士雄:妊娠授乳期乳癌. 乳癌の臨床1990;5:639-652

• 15) 沢野 彰, 木村道夫, 秋元 実, ほか:妊娠授乳期乳癌の特徴. 臨床外科1986;41:1311-1315

• 16) 元村和由, 野口新三郎, 小山博記, ほか:術後補助化学療法の有用性-乳癌. 癌と化学療法 1997;24:1239-1244

• 17) 高嶋成光:最新の乳癌化学療法. 化学療法の領域1998;14:256-265

• 18) 堀越 昇, 高橋俊二, 石塚 光, ほか:新しい乳癌化学療法. 乳癌の臨床1997;12:274-281

• 19) Abe O:The role of chemoendocrine agents in postoperative adjuvant therapy for breast cancer:Meta-analysis of the collaborative of postoperative adjuvant chemoendocrine therapy for breast cancer (ACETOBC). Breast Cancer 1994;1:1-9

• 20) Abe R, Tuchiya A, Koike H, et al:A cooperative randomized controlled study of adjuvant chemoendocrine therapy for breast cancer in Japan. Am J Clin Oncol 1994;17:103-108

• 21) 野村雍夫:抗癌剤の特徴と新しい使い方. 癌と化学療法1997;24:1911-1915

• 22) Wada T, Yamauchi E, Houjou T, et al:Conventional dose CAF therapy versus low dose adriamycin therapy in treatment of advanced breast cancer. Breast Cancer 1994;1:51-56

• 23) 和田富雄:乳癌の化学内分泌療法. 外科1995;57:548-555

• 24) 和田富雄:乳癌のホルモン療法. 産婦人科の世界1997;49:217-225

• 25) 安達 勇, 岡元るみ子, 渡辺 亨, ほか:最新の乳癌治療-内分泌, 化学療法の現状. 外科診療1994;36:731-739

III 乳房疾患の診断法

P.106 掲載の参考文献

• 1) 日本乳癌学会(編):臨床・病理乳癌取扱い規約, 第13版. 1998, 金原出版, 東京

• 2) 坂元吾偉:乳腺腫瘍病理アトラス, 第2版. 1995, 篠原出版, 東京

• 3) 坂元吾偉(編):取扱い規約に沿った腫瘍鑑別診断アトラス-乳腺. 1992, 文光堂, 東京

• 4) 長村義之, 秋山 太(編):生検鑑別診断アトラス, 乳腺生検診断-進め方・考え方. 1997, 文光堂, 東京

P.114 掲載の参考文献

• 1) 阿部力哉:乳癌検診の進め方. 外科治療1996;74:48-53

• 2) Abe R, Kimura M, Sato T, et al:Trial of early detection of breast cancer by mass screening. Cancer 1995;54:1479-1483

• 3) 浅越辰男, 花上 仁, 四方淳一, ほか:早期乳癌の診断. 日本癌治療学会誌1987;22:2202-2209

• 4) 浅越辰男:T1・T2乳癌患者診療の流れ. 乳癌の臨床1998;13:21-28

• 5) 森谷卓也, 真鍋俊明:乳腺症. 病理と臨床1994;12:682-689

• 6) 土屋真一:乳腺線維腫. 病理と臨床1994;12:675-681

• 7) 浅越辰男, 花谷勇治, 四方淳一, ほか:非浸潤癌と触知不能乳癌の診断における乳管区域切除の有用性. 日本臨床外科医学会雑誌1990;51:2598-2602

• 8) 大内憲明:乳管小葉区域切除. 乳癌の手術, 改訂第2版(霞富士雄, 監). 1998;pp186-193, 南江堂, 東京

P.127 掲載の参考文献

• 1) 植野 映:リアルタイム乳房超音波診断. 1991, 南江堂, 東京

• 2) Dussik KT, Dussik F, Wyt L:Auf dem Wege zur Hyperphonographie des Gehirnes. Wien Med Wochenschr 1947;97:425-429

• 3) Wild JJ:Further pilot echographic studies of the histologic structure of tumors of the living intact human breast. Am J Pathol 1952;28:839-861

• 4) Kikuchi Y, Wagai T, Tanaka K, et al:Early cancer diagnosis through ultrasonics. J Acoust Soc Am 1957;29:824-833

• 5) Wagai T:Dawn of breast ultrasound. Textbook of International Breast Ultrasound Seminar. 1994;pp11-14, IBUS

• 6) 菊池喜充:超音波断層法における感度断層の意義と問題点. 日本超音波医学会研究発表会講演論文集1970;18:61-62

• 7) Hirano T, Takamizawa K, Sasaki H, et al:Annular array for imaging superficial organs. Topics in Breast Ultrasound (Kasumi F, Ueno E, eds), 1991;pp137-142, Shinohara Pubiishers, Tokyo

• 8) Tanaka Y, Takehara Y, Kawauchi A, et al:The development of new high resolution ultrasonic equipment for surface organs. Topics in Breast Ultrasound (Kasumi F, Ueno E, eds). 1991;pp143-146, Shinohara Publishers, Tokyo

• 9) Kossoff G:Improved techniques on ultrasonic cross-sectional echography. Ultrasonics 1972;10:221-227

• 10) 内田六郎, 萩原芳夫, 入江喬介:電子走査超音波診断装置. 日本超音波医学会研究発表会講演論文集1971;19:65-66

• 11) 大東弘二:高分子圧電膜トランスデューサーとその応用. 超音波医学1980;7:365-370

• 12) 斉藤 毅, 浅岡善雄, 伊東紘一:メカニカルセクター高速走査装置による乳房超音波検査. 日本超音波医学会研究発表会講演論文集1985;46:329-330

• 13) Rizzatto G:lnstrumentation. Ultrasound of Superficial Structures (Solbiati L Rizzatto G, eds). 1995;pp3-21, Churchill Livingstone, New York

• 14) 小西 豊, 小県正明, 黒木輝夫, ほか:超音波画像上限局型腫瘤像を示す乳腺症とT1乳癌の鑑別診断についての一考察. 超音波医学1988;15:420-427

• 15) Ueno E, Tohno E, Soeda S, et al:Dynamic tests in real-time breast echography. Ultrasound Med Biol 1988;14 (suppl 1):53-57

• 16) Wells PNT:Handbook of Clinical Ultrasound. 1978;p18, John Wiley & Sons, New York

• 17) Fields S, Dunn F:Correlation of echographic visualizability of tissue with biological composition and physiological state. J Acoust Soc Am 1973;54:809-812

• 18) Calderon C, Vilkomerson D, Merzich R, et al:Difference in the attenuation of ultrasound by normal, benign, and malignant breast tissue. J Clin Ultrasound 1976;4:249-257

• 19) Kobayashi T:Diagnostic ultrasound in breast cancer:Analysis of retrotumorous echo patterns correlated with sonic attenuation by cancerous connective tissue. J Clin Ultrasound 1979;7:471-479

• 20) 植野 映, 上田光宏, 田部井誠, ほか:乳房組織および乳房腫瘍の超音波速度. 日本超音波医学会研究発表会講演論文集1985;12:161-162

• 21) 植野 映, 伊東紘一, 斉藤 建, ほか:乳腺疾患の超音波断層像と病理組織像との比較検討. 超音波医学1981;8:123-132

• 22) Ueno E, Tohno E, Itoh K:Classification and diagnostic criteria. Jpn J Med Ultrasonics 1986;13:19-31

• 23) 角田博子, 東野英利子, 植野 映:乳癌の乳管内進展の超音波画像. 日本超音波医学会研究発表会講演論文集1988;52:217-218

• 24) 角田博子, 植野 映, 東野英利子, ほか:乳癌の乳管内進展の超音波画像. 超音波医学1990;17:44-49

• 25) Chersevsani R, Tsunoda-Shimizu H, Giuseppetti GM, et al:Breast. Ultrasound of Superficial Structures (Solbiati L, Rizzatto G, eds). 1995;pp141-190, Churchill Livingstone, New York

• 26) Osteen RT, Connolly JL, Recht A, et al:Identification of patients at high risk for local recurrence after conservative surgery and radiation therapy for stage I or II breast cancer. Arch Surg 1987;122:1248-1252

• 27) 高島成光:マンモグラフィの石灰化-乳房温存療法の指標としての石灰化像. 乳癌の臨床 1994;9:403-411

• 28) 角田博子, 植野 映, 東野英利子, ほか:乳癌の乳管内進展の評価と乳房温存療法の応用. 日本超音波医学会研究発表会講演論文集1993;20:459-460

• 29) 高崎雅子, 植野 映, 東野英利子, ほか:異常乳頭分泌の超音波検査. 日本超音波医学会研究発表会講演論文集1985;47:155-156

• 30) Kamio T, Kameoka S, Muraki H, et al:Significance of ductal findings in ultrasonic examination of the breast:Diagnosis of intraductal tumor and intraductal spreading of breast cancer. Topics in Breast Ultrasound (Kasumi F, Ueno E, eds). 1991;pp200-205, Shinohara Publishers, Tokyo

• 31) Cosgrove DO, Bamber JC, Davey JB, et al:Color Doppler signals from breast tumors. Radiology 1990;176:175-180

• 32) 濱田充生, 小西 豊, 島田啓子, ほか:乳腺疾患におけるドプラ法の有用性について-拍動性血流シグナルの検出率およびその波形分析の意義についての再検討. 超音波医学1995;22:253-260

• 33) Kawauchi A, Shiga T, Naito S, et al:Clinical evaluation of ultrasonic colour Doppler. Topics in Breast Ultrasound (Kasumi F, Ueno E, eds). 1991;pp210-215, Shinohara Publishers, Tokyo

• 34) 島田啓子, 小西 豊, 濱田充生, ほか:乳腺腫瘤での腫瘤内血流分析による良悪性の鑑別. 日本超音波医学会研究発表会講演論文集1992;60:215-216

• 35) Ueno E, Tsunoda-Shimizu H, Nakamura N, et al:Colour Doppler imaging for the diagnosis of solid breast masses. Topics in Breast Ultrasound (Kasumi F, Ueno E, eds). 1991;pp58-62, Shinohara Publishers, Tokyo

• 36) Ueno E, Tohno E:Spectoral and color Doppler signals related to pathology. Ultrasound of Superficial Structures (Solbiati L, Rizatto G, eds). 1995;pp41-48, Churchill Livingstone, New York

• 37) 日本超音波医学会医用超音波診断基準に関する委員会:乳房の超音波診断基準. 超音波医学 1989;16:106-107

• 38) Yokozawa T, Kuma K, Miyauchi A, et al:Accurate and simple method of diagnosing thyroid nodules by the modified technique of ultrasound guided fine needle aspiration biopsy, Thyroid 1995;5:141-145

• 39) 植野 映, 角田博子, 平野 稔, ほか:乳癌の観血的診断法. 画像診断1991;11:159-176

• 40) Nath ME, Robinson TM, Tobon H, et al:Automated large-core needle biopsy of surgically removed breast lesions:Comparison of samples obtained with 14-, 16-, and 18-gauge needles. Radiology 1995;197:739-742

• 41) Ueno E, Aiyoshi Y, Imamura A, et al:Ultrasonically guided biopsy of nonpalpable lesions of the breast by the spot method. Surg Gynecol Obstet 1990;170:153-155

• 42) Ueno E, Yano Y, Yashiro T, et al:Ultrasonically Guided Intra-arterial Chemotherapy for Locally Advanced Breast Cancer (LABC). Senology, Monduzzi Editore, Sp. A, Bologna, 1998;pp381-384

P.139 掲載の参考文献

• 1) Salomon A:Beitrage zur Pathologie und Klinik der Mamma Karzinom. Arch Klin Chir 1913;103:573-668

• 2) Ostrum BJ:Low dose mammography. Radiology 1973;109:323-326

• 3) 大内憲明:マンモグラフィを導入した乳がん検診の実施体制についての調査研究-研究報告書. 1998. 3

• 4) 日本医学放射線学会乳房撮影ガイドライン委員会(編):乳房撮影ガイドライン. 1995;pp62-71, 日本アクセル・シュプリンガー出版, 東京

• 5) 森本忠興, 笹 三徳, 山口哲史, ほか:徳島県におけるマンモグラフィ導入検診の成績. 厚生省がん助成金による研究「マンモグラフィ導入による乳癌検診の精度管理の確立に関する研究」平成8年度研究報告. 1997;pp21-27

• 6) 遠藤登喜子, 岩瀬拓士, 大貫幸二, ほか:乳房画像診断用語集 Breast Imaging Lexicon. 日本乳癌検診学会誌1998;7:63-70

• 7) 遠藤登喜子, 岩瀬拓士, 大貫幸二, ほか:検診マンモグラムにおける読影所見の記載方法Reporting System. 日本乳癌検診学会誌1998;7:71-73

P.149 掲載の参考文献

• 1) 片田和廣:ヘリカルスキャンの基礎と臨床(木村和衛, 古賀佑彦, 編). 1993;pp141-152, 医療科学社, 東京

• 2) 佐古正雄, 杉本幸司:造影手技のポイント-画像診断セミナー2(平松京一, 編). 1993;pp 13-21, 秀潤社, 東京

• 3) Chang CH, Sibala JL, Fritz SL, et al:Computed tomographic evaluation of the breast. AJR Am J Roentgenol 1978;131:459-464

• 4) Muller JW, van Waves PF, Koehler PR:Computed tomography of breast lesions:Comparison with x-ray mammography. J Comput Assist Tomogr 1983;7:650-654

• 5) 井上善弘, 森 耕一, 福田穂積, ほか:マンモグラフィで腫瘤影を確認できない乳癌のCT所見. 臨床放射線1992;37:873-876

• 6) Kormano M, Dean PB:The major component of contrast enhancement. Radiology 1976;121:379-382

• 7) Gilles R, Zafrani B, Guinebretiere JM:Ductal carcinoma in situ:MR imaging-Histopathologic correlation. Radiology 1995;1961:415-419

• 8) Yoshikawa J, Matsui O, Kadoya M, et al:Delayed enhancement of fibrotic areas in hepatic masses:CT-pathologic correlation. J Comput Assist Tomogr 1992;16:206-211

• 9) Gisvold JJ, Reese DF, Karsell PR:Computed tomographic mammography (CTM). AJR Am J Roentgenol 1979;133:1143-1149

• 10) 前田 学, 峯 博子, 鈴木 均, ほか:Low-dose mammography systemによる乳房血管撮影の経験. 日本医学放射線学会雑誌1977;37:1101-1108

• 11) Weidner N, Semple JP, Welch WR, et al:Tumor angiogenesis and metastasis:Correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8

• 12) Roland H, James LC, Rebecca G, et al:The presence of intraductal component following a limited excision correlates with prominent residual disease in the remainder of the breast. J Clin Oncol 1990;8:113-118

• 13) 岩瀬拓士, 霞富士雄, 渡辺進, ほか:予後からみた適応, Q+Ax 100症例の検討から Lumpectomy+Radiationを考察する. 外科治療1990;62:391-398

• 14) 芳賀俊介, 蒔田益次郎, 清水忠夫, ほか:原発巣の進展形式からみた乳房温存療法の適応に関する研究. 日本外科学会雑誌1990;91:411-418

• 15) 月岡健雄, 川勝樹夫, 福永 淳, ほか:乳癌の乳管内進展におけるヘリカルCT所見. 日本医学放射線学会雑誌1996;56:S158

P.158 掲載の参考文献

• 1) Bovee W, Getreuer K, Smidt J, et al:Nuclear magnetic resonance detection of human breast tumors. J Natl Cancer Inst 1978;61:53-55

• 2) Ross RJ, Thompson JS, Kim K, et al:Nuclear magnetic resonance imaging and evaluation of human breast tissue:Preliminary clinical trials. Radiology 1982;143:195-205

• 3) El Yousef SJ, Duchesneau RH, Alfidi RJ, et al:Magnetic resonance imaging of the breast-Work in progress. Radiology 1984;150:761-766

• 4) Mans field P, Morris PG. Ordidge R:Carcinoma of the breast imaged by NMR. Br/Radiol 1979;52:242-243

• 5) Heywang SH, Hahn D, Schmidt H, et al:MR imaging of the breast using gadolinium-DTPA. J Comput Assist Tomogr 1986;10:199-204

• 6) 高原太郎, 中島康雄, 福田 護, ほか:乳腺の画像診断, 画像診断各論-MR imaging of breast. 日獨医報1995;40:530-548

• 7) Friedrich M:MRI of the breast:State of art. Eur Radiol 1998;8:707-725

• 8) Heywang-Kobrunner SH, Beck R:Contrast-enhanced MRI of the Breast, 2nd ed. 1996, Springer, Berlin, Heidelberg, New York

• 9) Heywang-Kobrunner SH, Haustein J, Pohl C, et al:Contrast-enhanced MR imaging of the breast:Comparison of two different doses of gadopentetate dimeglumine. Radiology 1994;191:639-646

• 10) Folkman J, Shing Y:Angiogenesis. J Biol Chem 1992;267:10931-10934

• 11) Weidner N, Folkman J, Pozza F, et al:Tumor angiogenesis:A new significant and independent prognostic indicator in early-Stage breast Carcinoma. J Natl Cancer Inst 1992;84:1875-1887

• 12) Watt AC, Ackerman LV, Windham JP, et al:Breast lesions:Differential diagnosis using digital subtraction angiography. Radiology 1986;159:39-42

• 13) Weidner N, Semple JP, Welch WR, et al:Tumor angiogenesis and metastasis:Correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8

• 14) 高原太郎:k-space. MRI自由自在. 1999;pp157-170, メジカルビュー社, 東京

• 15) 高原太郎:MR-mammographyにおける乳癌進展範囲診断能と腫瘍周囲組織像の関連性についての研究. 日本磁気共鳴医学会雑誌1996;16:373-387

• 16) 輿石 剛, 磯本一郎, 中村和邦, ほか:脂肪抑制併用Dynamic MRIによる乳腺腫瘤の良悪性の鑑別について-定量的評価を用いた鑑別の試み. 日本医学放射線学会雑誌1998;58:433-440

• 17) Whitney WS, Herfkems RJ, Silverman J, et al:Gadolinium-enhanced spectral-spatial MR imaging for evaluation of breast carcinoma (abstr). Radiology 1993;189(P):136

• 18) Haase A, Frahm J, Hanicke W, et al:1H NMR chemical shift selective (CHESS) imaging. Phys Med Blip 1985;30:341-344

• 19) 高原太郎:基本的画像の種類と表示方法. MRI自由自在. 1999;pp71-89, メジカルビュー社, 東京

• 20) 中村清吾, 杉浦孝司, 西尾剛毅, ほか:乳房温存療法適応決定における三次元MRIの有用性. 乳癌の臨床1996;11:679-685

• 21) Keiser WA, Zeitler E:MR imaging of the breast:Fast imaging sequences with and without Gd-DTPA:Preliminary observations. Radiology 1989;170:681-686

• 22) Heywang SH, Wolf A, Pruss E, et al:MR imaging of the breast with Gd-DTPA:Use and limitations. Radiology 1989;171:95-103

• 23) Stack JP, Redmond OM, Codd MB, et al:Breast disease:Tissue characterization with Gd-DTPA enhancement profiles. Radiology 1990;174:491-494

• 24) Botes C, Barentsz JO, Mus RD, et al:MR characterization of suspicious breast lesions with a gadolinium-enhanced Turbo FLASH subtraction technique. Radiology 1994;193:777-781

• 25) Nunes LW, Schnall MD, Siegelman ES, et al:Diagnostic performance characteristics of architectural features revealed by high spatial-resolution MR imaging of the breast. AJR Am J Roentgenol 1997;169:409-415

• 26) 関 恒明, 蜂屋順一, 似鳥俊明, ほか:MRマンモグラフィー乳癌のMR像を中心として. 乳癌の臨床1996;11:232-242

• 27) Muller-Schimpfie M, Ohmenhauser K, Claussen CD:Effect of age and menstrual cycle on mammography and MR mammography. Radiologe 1997;37:718-725

• 28) 吉野綾子:乳腺腫瘤の鑑別におけるEcho-planar Imagingを用いたDynamic Susceptibility Contrast MRIの有用性について. 日本医学放射線学会雑誌1998;58:441-446

• 29) Boetes C, Strijk SP, Holland R, et al:False-negative MR imaging of malignant breast tumors. Eur Radiol 1997;7:1231-1234

• 30) Orel SG, Mendonca MH, Reynolds C, et al:MR imaging of ductal carcinoma in situ. Radiology 1997;202:413-420

• 31) Gilles R, Zafrani B, Guinebretiere JM, et al:Ductal carcinoma in situ:MR imaging-histopathologic correlation. Radiology 1995;196:415-419

• 32) 吉本賢隆, 多田隆士, 霞富士雄:MRIによる乳癌の進展度診断. 臨床画像1997;13:410-416

• 33) 川島博子, 木村真里, 鈴木正之, ほか:造影MRIの実際-乳腺. 臨床画像1996;12:1440-1450

• 34) 平松秀子, 池田 正, 榎本耕治, ほか:乳管内進展病巣の検出におけるhigh resolution MRIの有用性. 日本医学放射線学会雑誌1997;57:182-188

• 35) 深津 博, 安藤容子, 石垣武男:MR mammographyによる乳癌の診断-とくに病変の乳管内進展について. 臨床放射線1996;41:975-980

P.166 掲載の参考文献

• 1) Teboul M:Echo-histological "acino-ductal analysis":Preliminary results. Ultrasound Med Biol 1988;14 (suppl I):89-95

• 2) 蒔田益次郎, 坂元吾偉, 難波 清, ほか:乳管内視鏡. 乳癌の臨床1988;4:571-575

• 3) Okazaki A, Okazaki M, Asaishi K, et al:Fiberoptic ductoscopy of the breast:A new diagnostic procedure for nipple discharge. Jpn J Clin Oncol 1991;21:188-193

• 4) 長瀬慈村, 江淵正和, 遠藤光夫:乳管内視鏡の現状と今後の展開. 乳癌の臨床1994;9:78-79

• 5) 神尾孝子:乳管内視鏡装置および手技. 乳癌の臨床1995;10:61-70

• 6) 佐伯菊子, 坂元吾偉, 秋山 太, ほか:乳管内視鏡による乳管内生検法の意義. 乳癌の臨床 1992;71404-410

• 7) 坂元吾偉, 秋山 太:乳腺腫瘍の病理組織診断の現状と問題点-乳頭状病変を中心に. 乳癌の臨床1993;8:528-534

• 8) 蒔田益次郎, 青山英子, 水谷三浩, ほか:乳管鏡による腫瘤非触知異常乳頭分泌症例の診断指針. 乳癌の臨床1997;12:706-710

• 9) 長瀬慈村:乳管内視鏡所見の読影と治療への応用. 乳癌の臨床1995;10:263-273

P.178 掲載の参考文献

• 1) 田中 昇, 金子 仁, 田島基男, ほか:Papanicolaou分類とその意義. 細胞診教本-その基礎と実際(田中 昇, 編). 1988;pp105-106, 宇宙堂八木書店, 東京

P.185 掲載の参考文献

• 1) 阿部力哉:診察と検査・診断-外科的生検. 新外科学大系18, 乳房の外科. 1988:pp85-89, 中山書店, 東京

• 2) 乳癌研究会:第43回乳癌研究会記録. 主題II, 生検, アンケート集計報告. 日本癌治療学会誌 1987:22:2477-2493

• 3) 園尾博司, 妹尾亘明:乳頭異常分泌症. 手術1986:20:537-545

• 4) 稲治英生, 元村和由, 野口眞三郎, ほか:乳腺良性疾患の診断と治療. 乳管内乳頭腫の診断と治療. 外科治療 1998:78:313-317

• 5) 岩瀬拓士, 吉本賢隆, 渡辺 進, ほか:非触知乳癌の生検. 乳癌の臨床1991:6:475-486

• 6) Hasselgren PO, Hummel RP, Fieler MA:Breast biopsy with needle localization:Influence of age and mammographic feature on the rate of malignancy in 350 breast nonpalpable lesions. Surgery 1991;110:623 628

• 7) Kopalls DB:Imaging-guided needle placement for biopsy and the preoperative localization of clinically occult lesions. Breast Imaging (Kopans DB, ed). 2nd ed. 1998:pp637-720. Lippincott-Raven, Philadelphia

• 8) Rosato EF, Curcillo H PG:Surgical Considerations in the management of breast cancer. Breast Caricer Treatment:A Comprehensive Guide to Management (Fowble B. et al, eds), 1991:pp89-104, Mosby-Year Book, St Louis

• 9) Reynolds HE, Jackson VP:Sonographically guided interventional procedures. Diagnosis of Diseases of the Breast (Bassett LW, Jackson V P, eds), 1997;pp263-273. WB Saunders, Philadelphia

• 10) 秋山太, 坂元吾偉, 岩瀬拓士, ほか:Probe Lumpectomy-乳房温存療法の新しい試み. 乳癌の臨床1993:8:409-414

• 11) 高橋かおる:乳癌に対するprobe lumpectomyの方法と限界. 乳腺疾患診断のKnack & Pitfalls -乳腺外科の要点と盲点(幕内雅敏, 監:霞富士雄, 編). 1998:pp70-72, 文光堂, 東京

• 12) 岩瀬拓士, 吉本賢隆, 渡辺 進, ほか:非触知石灰化病変の診断. 乳癌の臨床1994:9:393-402

• 13) 大住省三, 佐伯峻昭, 西本直樹, ほか:マンモグラフィで発見された触知不能病変の検討. 乳癌の臨床1997:12:689-695

• 14) 白井博之, 高橋 節, 村田陽子, ほか:三次元生検装置による穿刺吸引細胞診にて確定診断した非触知同側多発乳癌の1例. 乳癌の臨床1997:12:573-576

• 15) Bauer TL Pandelidis SM, Rhoads JE, et al:Mammographically detected carcinoma of the breast. Surg Gynecol Obstet 1991:173:482-486

• 16) 森本忠興, 石田常博, 福田 護, ほか:マンモグラフィを導入した乳癌検診システムのガイドライン(案). 日乳癌検診学会誌1996;5:299-307

• 17) 乳頭分泌液中CEA研究会;森 武貞, 稲治英生, 東山聖彦:乳頭分泌液中CEA測定用簡易キット(MS-1002)による乳癌診断能の検討. 乳癌の臨床1989;4:99-103

• 18) Dowlatshahi K, Yaremko ML, Klauskens LF, et al:Nonpalpable breast lesions:Findings of stereotaxic needle-core biopsy and fine needle aspiration cytology. Radiology 1991;181:745-750

• 19) 多田隆士, 岩瀬拓士, 吉本賢隆, ほか:Stereotaxic Core-Needle Biopsyによる微細石灰化病変診断の経験-LORAD社のStereo-Guide Breast Biopsy Systemによる. 乳癌の臨床1995;10:637-643

• 20) 林孝子:Stereotaxic core needle biopsyの方法と限界. 乳腺疾患診断のKnack & Pitfalls-乳腺外科の要点と盲点(幕内雅敏, 監;霞富士雄, 編). 1998;pp64-66, 文光堂, 東京

• 21) 辛栄成, 高塚雄一, 竹田雅司, ほか:乳腺腫瘤に対する生検の代用としてのCore Needle Biopsy の Pitfall. 乳癌の臨床1997;12:199-203

• 22) McCombs MM, Bassett LW, DeBruhl M, et al:Imaging-guided needle biopsy of the breast. Diagnosis of Diseases of the Breast (Bassett LW, Jackson VP, eds). 1997;pp251-261, WB Saunders, Philadelphia

• 23) Evans III WP:Stereotactic core breast biopsy. Diseases ofthe Breast (Harris JR, Lippman ME, Morrow M, et al, eds). 1996;pp145-152, Lippincott-Raven, Philadelphia

• 24) Fornage BD:Ultrasound-guided percutaneous needle biopsy on nonpalpable breast masses. Diseases of the Breast (Harris JR, Lippman ME, Morrow M, et al, eds). 1996;pp152-158, Lippincott-Raven, Philadelphia

• 25) Heywang-Kobrunner SH, Schaumloffel U, Lampe D, et al:Minimally invasive stereotaxic vacuum core breast biopsy. Eur Radiol 1998;8:377-385

P.194 掲載の参考文献

• 1) Herberman RB:Summary of discussion on generaly assay for immunodiagnosis of human cancer. Compendium of Assay for Immunodiagnosis of Human Cancer. Development in Cancer Research (Herberman RB, ed). 1979;pp3-5, Elsevier/North Holland Biomedical Press, Philadelphia

• 2) 石井 勝:腫瘍マーカーの定義と分類. 日本臨牀1996;54:1473-1478

• 3) Geraghty JG, Coveney EC, Sherry F, et al:CAI5-3 in patients with locoregional and metastatic breast carcinoma. Cancer 1992;70:2831-2834

• 4) 弥生恵司:乳頭分泌液中CEAとその臨床応用. 乳癌の臨床1992;7:366-374

• 5) Inaji H, Koyama H, Motomura K, et al:ErbB-2 protein levels in nipple discharge:Role in diagnosis of early breast cancer. Tumour Biol 1993;14:271-278

• 6) Inaji H, Koyama H, Motomura K, et al:Simultaneous assay of ErbB-2 protein and carcinoembryonic antigen in cyst fluid as an aid in diagnosing cyst lesions of the breast. Breast Cancer 1994;1:25-30

• 7) Hayes DF, Henderson IC, Shapiro CL, et al:Evaluation of patients after primary therapy. Diseases of the Breast(Harris JR, ed). 1996;pp629-647, Lippincott-Raven, Philadelphia

• 8) Tondini C, Hayes DF, Gelman R, et al:Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Res 1988;48:4107-4112

• 9) 吉本賢隆:乳癌と腫瘍マーカー-モニタリングマーカーとしての利用法と問題点について. 癌と化学療法1990;17:2277-2283

• 10) Kiang DT, Greenberg LJ, Kennedy BJ, et al:Tumor marker kinetics in the monitoring of breast cancer, Cancer 1990;65:193-199

• 11) Sonoo H, Kurebayashi J:Serum tumor marker kinetics and the clinical course of patients with advanced breast cancer. Surg Today 1996;26:250-257

• 12) 小川道雄:全身病(systemic disease)としての乳癌(II). 外科治療1998;78:249-261

• 13) Redding WH, Coombes RC, Monaghan P, et al:Detection of micrometastases in patients with primary breast cancer. Lancet 1983;ii:1271-1274

• 14) Miki Y, Swenson J, Scattuck ED, et al:A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71

• 15) Wooster R, Bignell G, Lancaster J, et al:Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789-792

• 16) Holzmayer TA, Hilsenbeck S, von Hoff DD, et al:Clinical correlates of MDRI (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Inst 1992;84:1486-1491

• 17) Hida T, Ariyoshi Y, Kuwabara M, et al:Glutathion S-transferase π levels in a panel of lung cancer cell lines and its relation to chemo-radiosensitivity. Jpn J Clin Oncol 1993;23:14-19

• 18) 海瀬博史, 日馬幹弘, 中山 俊, ほか:血清中VEGF定量(ELISA法)の意義と腫瘍マーカーとしての臨床応用の可能性について. 日本外科学会雑誌1998;99:504

• 19) Esteban JM, Schlom J, Gansow OA, et al:New method for the chelation of indium-111 to monoclonal antibodies:Biodistribution and imaging of athymic mice bearing human colon carcinoma xenografts. J Nucl Med 1987;28:861-870

• 20) Takahashi T, Yamaguchi T, Kitamura K, et al:Clinical application of monoclonal antibodydrug conjugates for immunotargeting chemotherapy of colorectal carcinoma. Cancer 1988;61:881-888

• 21) Clayman GL, el-Naggar AK, Roth JA, et al:In vivo molccular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res 1995;55:1-6

• 22) Gold P, Freedman SO:Demonstration of tumor-specific antigens in human colonic carcinoma by immunological tolerance and absorption techniques. J Exp Med 1965;121:439-462

• 23) 小川徹男:乳癌の腫瘍マーカーの現状. 乳癌の臨床1992;7:323-332

• 24) Mansour EG, Hastert M, Park CH, et al:Tissue and plasma carcinoembryonic antigen in early breast cancer:A prognostic factor. Cancer 1983;51:1243-1248

• 25) Esteban JM, Felder B, Ahn C, et al:Prognostic relevance of carcinoembryonic antigen and estrogen receptor status in breast cancer patients. Cancer 1994;74:1575-1583

• 26) Lee AK, Rosen PP, DeLellis RA, et al:Tumor marker expression in breast carcinomas and relationship to prognosis. Am J Clin Pathol 1985;84:687-696

• 27) van Dam PA, Keersmaeckers G, van Bockstaele DR, et al:DNA ploidy and the expression of tissue-carcinoembryonic antigen in grade III carcinoma of the breast. Eur J Obstet Gynecol Reprod Biol 1990;38:59-62

• 28) Hilkens J, Buijs F, Hilger J, et al:Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumor. Int J Cancer 1984;34:197-206

• 29) 妹尾亘明, 榎本耕治, 北村正次, ほか:各種腫瘍マーカーの乳癌診断-予後における評価. 乳癌の臨床1987;2:241-251

• 30) Martoni A, Ercolino L, Bellanova B, et al:CA 15. 3 and CEA plasma level monitoring in patients with breast cancer. Int J Biol Markers 1988;3:154-158

• 31) Hirohashi S, Watanabe M, Shimosato Y, et al:Monoclonal antibody reactive with the sialyl-sugar residue of a big molecular weight glycoprotein in sera of cancer patient. Jpn J Cancer Res (Gann) 1984;75:485-488

• 32) Watanabe M, Hirohashi S, Shimosato Y, et al:Carbohydrate antigen defined by a monoclonal antibody raised a gastric cancer xenograft. Jpn J Cancer Res (Gann) 1985;76:43-52

• 33) 高塚雄一, 岡村泰彦:腫瘍マーカーの現状と問題点-NCC-ST-439. 乳癌の臨床1992;7:333-340

• 34) Bjorklund B, Bjorklund V:Antigenicity of pooled human malignant and normal tissues by cytoimmunological technique:Presence of an insoluble, heat-labile tumor antigen. Int Arch Allergy 1957;10:153-184

• 35) Weber K, Osbom M, Moll R, et al:Tissue polypoid antigen (TPA) is related to the non-epidermal keratins 8, 18 and 19 typical of simple and non-squamous epithelia:Reevaluation of a human tumor marker. EMBO J 1984;3:2704-2714

• 36) Mesa-Tej ada R, Palakodety R, Leon A, et al:Immunocytochemical distribution of a breast carcinoma associated glycoprotein identified by monoclonal antibodies. Am J Pathol 1988;130:305-314

• 37) 妹尾亘明, 園尾博司:乳癌診断における腫瘍マーカーBCA225の有用性に関する検討. 乳癌の臨床1992;7:601-613

• 38) Colcer D, Hand PH, Nuti M, et al:A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc Natl Acad Sci USA 1981;78:3199-3203

• 39) Berruti A, Piovesan A, Torta M, et al:Biochemical evaluation of bone turnover in cancer patients with bone metastases:Relationship with radiograph appearances and disease extension. Br J Cancer 1996;73:1581-1587

• 40) Suva LJ, Winslow GA, Wettenhall RE, et al:A parathyroid hormone-related protein implicated in malignant hypercalcemia:Cloning and expression. Science 1987;237:893-896

• 41) Ikeda K, Ohno H, Hane M, et al:Development of a sensitive two-site immunoradioassay for parathyroid hormone-related protein:Evidence for elevated levels in plasma from patients with adult T-cell leukemia/lymphoma and B-cell lymphoma. J Clin Endocrinol Metab 1994;79:1322-1327

• 42) Tsuda H, Hirohashi S, Shimosato Y, et al:Immunohistochemical study on overexpression of c-erbB-2 protein in human breast cancer:Its correlation with gene amplification and long-term Survival Of patients. Jpn J Cancer, Res 1990;81:327-332

• 43) 管野康吉, 河合 忠, 石井 勝, ほか:EIAキットによる血清ErbB-2の臨床的検討. 癌と化学療法1994;21:1255-1262

• 44) Muss HB, Thor AD, Berry DA, et al:c-erb-B-2 expression and response to adjuvant therapy in woman with node-positive early breast cancer. N Engl J Med 1994;330:1260-1266

IV 乳房の良性疾患

P.204 掲載の参考文献

• 1) Gould BK, Randall RV, Kempers RD, et al:Galactorrhea. 1974;pp3-100, Charles C Thomas, Springfield

• 2) Cowie AT, Tindall JS:The Physiology of Lactation. 1971, Arnold, London

• 3) Aono T, Miyake A, Shioji T, et al:Impaired LH release following exogenous estrogen administration in patients with amenorrhea-galactorrhea syndrome. J Clin Endocrinol Metab 1976;42:696-702

• 4) 倉智敬一, 青野敏博, 小池浩司, ほか:Bromocriptine (Parlodel(R))による乳汁漏出症の治療成績. 産科と婦人科1981;48:241-248

• 5) Chiari J, Braun K, Spath J:Klinik der Geburtshilfe und Gynakologie. 1855, Erlangen

• 6) Argonz J, del Castillo EB:Syndrome characterized by estrogenic deficiency, galactorrhea and decreased urinary gonadotropin. J Clin Endocrinol 1953;13:79-87

• 7) Aono T, Shioj i T, Kinugasa T, et al:Clinical and endocrinological analyses of patients with galactorrhea and menstrual disorders due to sulpiride or metoclopramide. J Clin Endocrinol Metab 1978;47:675-680

• 8) Dickey RP, Stone SC:Drugs that affect the breast and lactation. Clin Obstet Gynecol 1975;18:95-111

• 9) Aono T, Shioji T, Onishi T, et al:Pregnancy following thyroid hormone treatment in a patient with amenorrhea-galactorrhea due to primary hypothyroidism. Fertil Steril 1977;28:878-880

• 10) Hollenhorst RW, Younge BR:Ocular manifestations produced by adenomas of the pituitary gland:Analysis of 1000 cases. Diagnosis and Treatment of Pituitary Tumors (Kohler PO, Ross GT, eds). 1973;pp53-64, Excerpta Medica, Amsterdam

• 11) 青野敏博:高プロラクチン血症の診断. 図説プロラクチン. 1985;pp57-64, 医歯薬出版, 東京

• 12) 青野敏博, 熊本悦明, 佐々木康人, ほか:WHO標準品を用いた血中プロラクチンのimmunoradiometric 測定法(スパック-Sプロラクチンキット)の多施設における基礎的および臨床的検討. ホルモンと臨床1989;37:87-101

• 13) Pepperell RJ, Aust F:Prolactin and reproduction. Fertil Steril 1981;35:267-274

• 14) Onishi T, Miyai K, Aono T, et al:Primary hypothyroidism and galactorrhea. Am Med 1977;63:373-378

• 15) Syvertsen A, Haughton VM, Williams AL, et al:The computed tomographic appearance of the normal pituitary gland and pituitary microadenomas. Radiology 1979;133:389-391

• 16) Pojunas KW, Daniels DL, Williams AL, et al:MR imaging of prolactin-secreting microadenomas. AJNR Am J Neuroradiol 1986;7:209-213

• 17) Kirschner MA:The role of hormones in the etiology of human breast cancer. Cancer 1977;39:2716-2726

• 18) Ciccarelli E, Savino L, Carlevatto V, et al:Vertebral bone density in non-amenorrhoeic hyperprolactinaemic women. Clin Endocrinol (Oxf) 1988;28:1-6
  pubmed

• 19) Hardy J, Beauregard H, Robert F:Prolactin secreting pituitary adenomas:Transsphenoidal microsurgical treatment. Progress in Prolactin Physiology and Patholgy (Robyn C, Harter M, eds). 1978;pp361-370, Elsevier/North Holland Biomedical Press, Amsterdam

• 20) Fluckiger E, Wagner H:2-Br-α-ergokryptin:Beeinflussung von Fertilitat und Laktation bei der Ratte. Experientia 1968;M:1130-1131

• 21) Speroff L, Glass RH, Kase NG:The Breast. Clinical Gynecologic Endocrinology and Infertility. 1994;pp547-582, Williams & Wilkins, Baltimore

• 22) 青野敏博:高プロラクチン血症治療薬. テルグリド. カレントテラピー1995;13:146-148

• 23) Thoner MO, Evans WS, MacLeod RM, et al:Ergot compounds and brain function-Neuroendocrine and neuropsychiatric aspects. Hyperprolactinemia:Current Concepts of Managemet Including Medical Therapy with Bromocriptine (Thormer MO, Calne DB, Lieberman A, eds). 1980;pp165-189, Raven Press, New York

P.211 掲載の参考文献

• 1) 秋山 太, 池田 正, 坂元吾偉, ほか:乳腺症の基礎と臨床-乳腺症カンファレンス. 癌の臨床1995;41:321-330

• 2) Hughes LE:Aberrations of normal development and involution (ANDI):An update. Recent Developments in the Study of Benign Breast Diseases (Mansel RE, ed). 1994;pp65-74, Parthenon Publishing, London

• 3) 吉田浩己:実験病理学の乳腺症. 乳腺症の臨床(坂本吾偉, 監). 1997;pp23-29, 篠原出版, 東京

• 4) Rosen PP, Oberman HA:Atlas of Tumor Pathology, 3rd series-Tumors of the Mammary Gland. 1993;pp49-66, AFIP, Washington DC

• 5) 坂元吾偉:乳腺症. 乳腺腫瘍病理アトラス, 第2版. 1995;pp111-124, 篠原出版, 東京

• 6) 秋山 太, 坂元吾偉:乳腺症の病理診断の現状. 癌の臨床1997;43:6-10

• 7) 池田 正:日本における乳腺症の概念と診断の現状に関するアンケート結果. 癌の臨床1997;43:1-5

• 8) Cancer Committee of the College of American Pathologist:Is "fibrocystic disease" of the breast precancerous? Arch Pathol Lab Med 1986;110:171-173

• 9) 弥生恵司, 妹尾 明, 泉 雄勝, ほか:Danazolの乳腺症に対する臨床的検討-プラセボを対照とした多施設二重盲検比較試験. 薬理と治療1991;19:3175-3188

• 10) Mansel RE:Guidelines for referral by general practitioners. Recent Developments in the Study of Benign Breast Diseases (Mansel RE, ed). 1994;pp25-32, Parthenon Publishing, London

P.222 掲載の参考文献

• 1) 坂元吾偉:乳腺腫瘍病理アトラス. 1987;pp9-19, 87-97, 篠原出版, 東京

• 2) 岩瀬拓士, 坂元吾偉, 蒔田益次郎, ほか:年齢から見た乳腺良性疾患-局麻下生検1, 048症例の検討. 乳癌の臨床1990;5:151-155

• 3) Rosen PP:Breast Pathology. 1997;pp143-175, Lippincott-Raven, Philadelphia

• 4) 野口眞三郎, 相原智彦, 元村和由, ほか:乳腺腫瘍のclonalityの解析. 癌の臨床1996;42:1581-1587

• 5) 長村義之, 秋山 太:乳腺生検診断-進め方・考え方. 1997;pp120-127, 文光堂, 東京

• 6) Page DL, Anderson TJ:Diagnostic Histopathology of the Breast. 1987;pp341-350, Churchill Livingstone, London

• 7) 渡辺 進, 梶谷 鎧, 坂元吾偉, ほか:乳腺の悪性葉状腫瘍. 乳癌の臨床1986;1:122-124

• 8) 長瀬慈村, 坂元吾偉, 秋山 太, ほか:悪性葉状腫瘍の臨床病理学的検討. 第54回日本癌学会総会記事1995;p537

• 9) 森園英智, 長瀬慈村, 岩井武尚:乳腺葉状腫瘍のDynamic MRI. 日本臨床外科医学会雑誌 1998(増刊号):433

• 10) 長瀬慈村:乳房の臨床-乳腺疾患を理解するために. 乳管内視鏡(Mammoscopy)の臨床的有用性. 1997;pp164-173, 医学の世界社, 東京

V 乳房の悪性疾患

P.231 掲載の参考文献

• 1) 富永祐民, 吉田 穣, 高谷 治, ほか:乳癌のhigh risk groupとは. 乳癌の臨床1988;3:251-271

• 2) Adami HO, Adams D, Boyle P, et al:Breast-cancer etiology. Int J Cancer (suppl) 1990;5:22-39

• 3) Kelsey JL:Breast cancer epidemiology:Summary and future directions. Epidemiol Rev 1993;15:256-263

• 4) Hunter DJ, Willett WC:Nutrition and breast cancer. Cancer Causes Control 1996;7:56-68

• 5) Tominaga S, Kuroishi T, Aoki K (eds):Cancer Mortality Statistics in 33 Countries 1953-1992. 1998, IUAC, Roppo Shupan, Nagoya

• 6) 厚生省統計情報部(編):人口動態統計, 1950-1996. 厚生統計協会, 東京

• 7) The Research Group for Population-based Cancer Registration in Japan:Cancer incidence and incidence rates in Japan in 1992-93:Estimates on data from seven population-based cancer registries. Jpn J Clin Oncol 1998;28 641-647

• 8) 黒石哲生, 広瀬かおる, 田島和雄, ほか:日本のがん死亡の将来予測. がん統計白書-罹患/死亡/予後-1999. 1999;pp17H85, 篠原出版, 東京

• 9) 北川貴子, 津熊秀明, 味木和喜子, ほか:日本のがん罹患の将来予測-1975〜93年の全国罹患率(推計値)に基づく将来推計. がん統計白書-罹患/死亡/予後-1999. 1999;pp159-170, 篠原出版, 東京

• 10) 三浦重人, 霞富士雄, 岩瀬拓士, ほか:日本人乳癌の家族発生. 乳癌の臨床1992;7:237-247

• 11) 三木義男:遺伝性乳癌の遺伝子診断. 家族性乳癌(阿部力哉, 監). 1996;pp35-50, 篠原出版, 東京

• 12) Dupont WD, Page DL:Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312:146-151

• 13) Nomura Y, Tashiro H, Katsuda Y:Benign breast disease as a breast cancer risk in Japanese women. Jpn J Cancer Res 1993;84:938-944

• 14) 平山 雄:大規模コホート研究に基づく乳がんの危険因子. CRC 1993;2:626-634

• 15) MacMahon B, Cole P, Brown J:Etiology of human breast cancer:A review. J Natl Cancer Inst 1973;50:21-42

• 16) Hirose K, Tajima K, Hamajima N, et al:A large-scale, hospital-based case-control study of risk factors of breast cancer according to menopausal status. Jpn J Cancer Res 1995;86:146-154

• 17) Yoo KY, Tajima K, Kuroishi T, et al:Independent protective effect of lactation against breast cancer:A case-control study in Japan. Am J Epidemiol 1992;135:726-733

• 18) Collaborative Group on Hormonal Factors in Breast Cancer (Beral V, et al):Breast cancer and hormone replacement therapy:Collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 1997;350:1047-1059

• 19) Romieu I, Berlin JA, Colditz G:Oral contraceptives and breast cancer. Cancer 1990;66:2253-2263

• 20) 土橋一慶:ホルモン補充療法と乳癌. 日本乳癌検診学会誌1998;7:237-246

• 21) World Cancer Research Fund in association with American Institute for Cancer Research:Food, Nutrition and the Prevention of Cancer:A Global Perspective. 1997;pp252-287, The American Institute for Cancer Research, Washington DC

• 22) Howe GR, Hirohata T, Hishop TG, et al:Dietary factors and risk of breast cancer:Combined analysis of 12 case-control studies. J Natl Cancer Inst 1990;82:561-569

• 23) Shimizu H, Ross RK, Bernstein L, et al:Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br J Cancer 1991;63:963-966

• 24) 坂元吾偉:肥満と乳癌. 図説臨床「癌」シリーズNo 8, 乳癌(高山昭三, 阿部令彦, 編). 1986;pp177-183, メジカルビュー社, 東京

• 25) Ueji M, Ueno E, Osei-Hyiaman D, et al:Risk factors for breast cancer among Japanese women:A case-control study in Ibaraki, Japan. Breast Cancer 1998;5:351-358

• 26) Hirose K, Tajima K, Hamajima N, et al:Efrect of body size on breast-cancer risk among Japanese women. Int J Cancer 1999;80:349-355

• 27) Rosenberg L, Metzger LS, Palmer JR:Alcohol consumption and risk of breast cancer:A review of the epidemiologic evidence. Epidemiol Rev 1993;15:133-144

• 28) Longnecker MP:Alcoholic beverage consumption in relation to risk of breast cancer:Meta-analysis and review. Cancer Causes Control 1994;5:73-81

• 29) Palmer JR, Rosenberg L:Cigarette smoking and the risk of breast cancer. Epidemiol, Rev 1993;15:145-156

• 30) Tokunaga M, Land CE, Yamamoto T, et al:Incidence of female breast cancer among atomic bomb survivors, Hiroshima and Nagasaki, 1950-1980. Radiat Res 1987;112:243-272

P.238 掲載の参考文献

• 1) Knudson AG Jr:Mutation and cancer:Statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971;68:820-823

• 2) Hussain SP, Harris CC:Molecular epidemiology of human cancer:Contribution of mutation spectra studies of tumor suppressor genes. Cancer Res 1998;58:4023-4037

• 3) Kinzler KW, Vogelstein B:Lessons from hereditary colorectal cancer. Cell 1996;87:159-170

• 4) Yu D, Jing T, Liu B, et al:Overexpression of ErbB2 blocks taxol-induced apoptosis by upregulation of p21CiP1, which inhibits p34Cdc2 kinase. Mol Cell 1998;2:581-591

• 5) Fredersdorf S, Burns J, Milne AM, et al:High level expression of p27ktPi and cyclin D1 in some human breast cancer cells:Inverse correlation between the expression of p27kiPi and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA 1997;94:6380-6385

• 6) 野水 整, 土屋敦雄, 阿部力哉:家族性乳癌:BRCA1, BRCA2遺伝子. Molecular Medicine 別冊, 家族性腫瘍. 1998;pp198-201, 中山書店, 東京

• 7) Miki Y, Swensen J, Shattuck-Eidens D, et al:A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71

• 8) Wooster R, Bignell G, Lancaster J, et al:Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789-792

• 9) Chen J, Silver DP, Walpita D, et al:Stable interaction between the products of the BRCAI and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol Cell 1998;21317-328

• 10) Baumann P, West SC:Role of human RAD51 protein in homologous recombination and double-stranded-break repair. Trends Biochem Sci 1998;23:247-251

• 11) Ludwig T, Chapman DL, Papaioannou VE, et al:Targeted mutations of breast cancer susceptibility gene homologs in mice:Lethal phenotypes of Brcal, Brca2, Brcal/Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes Dev 1997;11:1226-1241

• 12) Gowen LC, Avrutskaya AV, Latour AM, et al:BRCA1 required for transcription-coupled repair of oxidative DNA damage. Science 1998;281:1009-1012

• 13) Patel KJ, Vu VP, Lee H, et al:Involvement of Brca2 in DNA repair. Mol Cell 1998;1:347-357

• 14) http://www. nhgri. nih. gov/Intramuralresearch/Lab-transfer/Bic/
  pubmed

• 15) Emi M, Matsushima M, Katagiri T, et al:Multiplex mutation screening of the BRCA1 gene in 1000 Japanese breast cancers. Jpn J Cancer Res 1998;89:12-16

• 16) Szabo CI, King MC:Population genetics of BRCA1 and BRCA2. Am J Hum Genet 1997;60:1013-1020

• 17) Narod SA, Ford D, Devilee P, et al:An evaluation of genetic heterogeneity in 145 breast-ovarian cancer families. Breast cancer linkage consoritum. Am J Hum Genet 1995;56:254-264

• 18) 家族性腫瘍研究会倫理委員会:家族性腫瘍における遺伝子診断の研究とこれを応用した診療に関するガイドライン(案). Molecular Medicine別冊, 家族性腫瘍. 1998;pp376-400, 中山書店, 東京

• 19) Hacia JG, Brody LC, Chee MS, et al:Detection of heterozygous mutations in BRCA1 using high density oligonucleotide arrays and two-colour fluorescence analysis. Nat Genet 1996;14:441-447

• 20) Serova OM, Mazoyer S, Puget N, et al:Mutation in BRCA1 and BRCA2 in breast cancer families:Are there more breast cancer-susceptibility genes? Am J Hum Genet 1997;60:486-495

P.245 掲載の参考文献

• 1) 日本乳癌学会(編):臨床・病理乳癌取扱い規約, 第13版. 1998, 金原出版, 東京

• 2) WHO:Histological Typing of Breast Tumours, 2nd ed (International Histological Classification of Tumours No 2). 1981, World Health Organization, Geneva

• 3) UICC:TNM Classification of Malignant Tumours, 5th ed. 1997, John Wiley & Sons, New York

• 4) 坂元吾偉, 駒木幹正, 菅野晴夫, ほか:乳癌の組織学的波及度からみた症例分布と予後の臨床病理学的検討. 乳癌の臨床1989;4:399-406

• 5) Elston CW:Grading of invasive carcinoma of the breast. Diagnostic Histopathology of the Breast (Page DL, Anderson TJ, eds). 1987;pp300-311, Churchill Livingstone, London, New York

P.252 掲載の参考文献

• 1) 坂元吾偉:日本人乳癌の特性と未来. 乳癌の臨床1987;2:327-338

• 2) 今村 洋, 坂元吾偉, 秋山 太, ほか:非浸潤性乳管癌の亜型分類. 乳癌の臨床1993;8:561-567

• 3) Holland R, Peterse JL, Millis RR, et al:Ductal carcinoma in situ:A proposal for a new classification. Semin, Diagn Pathol 1994;11:167-180

• 4) Lagios M:Duct carcinoma in situ:Pathology and treatment. Surg Clin North Am 1990;70:853-871

• 5) von Dongen J, Holland R, Peterse J, et al:Ductal carcinoma in-situ of the breast. Eur J Cancer 1992;28:626-629

• 6) 今村 洋, 坂元吾偉, 秋山 太, ほか:乳腺の非浸潤性乳管癌の組織亜型分類別にみた浸潤能に関する検討. 乳癌の臨床1996;11:323-326

• 7) Patchefsky AS, Schwartz GF, Finkelstein SD, et al:Heterogeneity of intraductal carcinoma of the breast. Cancer 1989;63:731-741

• 8) 梶原哲郎, 清水忠夫, 飯田富雄, ほか:一側多発乳癌の臨床. KARKINOS 1992;5:493-498

• 9) Kasumi F, Iwase T, Yoshimoto M, et al:Experience of quadrantectomy with axillary dissection without radiotherapy sustained by serial pathological examination for stage I breast cancer. J Cancer Res Clin Oncol 1995;121:549-554

• 10) 霞富士雄:両側乳癌. 日本外科学会雑誌1985;86:266-279

• 11) 岩瀬拓士, 吉本賢隆, 霞富士雄, ほか:マンモグラフィー上の石灰化からみた乳房温存療法の適応. 乳癌の臨床1996;11:643-648

• 12) 関 恒明, 増田 裕, 蜂屋順一, ほか:乳房温存療法とMRI診断. 乳癌の臨床1996;11:672-678

• 13) 渡辺 修, 芳賀駿介, 清水忠夫, ほか:非浸潤性乳管癌に対する補助診断としてのIV-DSAの意義. 乳癌の臨床1996;11:553-558

• 14) 渡辺 修, 芳賀駿介, 清水忠夫, ほか:IV-DSAによる腫瘍濃染像からみた乳房温存療法の適応. 乳癌の臨床1996;11:686-692

• 15) 岡崎 亮, 岡崎 稔, 平田公一, ほか:乳管内視鏡. 乳癌の臨床1996;11:665-671

• 16) 蒔田益次郎, 難波 清, 青山英子, ほか:乳頭異常分泌を呈する乳癌の乳管内進展部の内視鏡分類と臨床像. 乳癌の臨床1996;11:303-309

• 17) 芝英一, 小林哲郎, 武田 力, ほか:乳腺腫瘤の穿針吸引細胞診. 乳癌の臨床1993;8:568-573

• 18) 秋山 太, 坂元吾偉, 岩瀬拓士, ほか:Probe Lumpectomy-乳房温存療法の新しい試み. 乳癌の臨床1993;8:409-414

• 19) 野口真三郎, 小山博記, 児玉 宏, ほか:早期乳癌935例に対する乳房温存療法の治療成績. 乳癌の臨床1994;9:565-572

• 20) Noguchi S, Koyama H, Kasugai T, et al:A case-control study on risk factors for local recurrence or distant metastases in breast cancer patients treated with breast-conserving surgery. Oncology 1997;54:468-474
  pubmed

P.260 掲載の参考文献

• 1) Rosen PP, Oberman HA:Intraepithelial (preinvasive or in situ) carcinoma. Atlas of Tumor Pathology-Tumors of the Mammary Gland. 1993;pp119-135, AFIP, Washington DC

• 2) Page DL, Anderson TJ:Anatomy. Diagnostic Histopathology of the Breast. 1987;pp4-10, Churchill Livingstone, Edinburgh

• 3) Foote FW, Stewart FW:Lobular carcinoma in situ. Am J Pathol 1941;17:491-495

• 4) Haagensen CD:Lobular neoplasia (lobular carcinoma in situ). Diseases of the Breast, 3rd ed (Haagensen CD, ed). 1986;pp192-241, WB Saunders, Philadelphia

• 5) Newman W:In situ lobular carcinoma of the breast:Report of 26 women and 32 cancers. Ann Surg 1963;157:591-599

• 6) Sunshine JA, Moseley HS, Fletcher WS, et al:Breast carcinoma in situ:A retrospective review of 112 cases with a minimum 10 year follow-up. Am J Surg 1985;150:44-49

• 7) Albonico G, Querzoli P, Ferretti S:Biological profile of in situ breast cancer investigated by immunohistochemical technique. Cancer Detect Prev 1998;22:313-318

• 8) Sakamoto G:Infiltrating carcinoma:Major histological types. Diagnostic Histopathology ofthe Breast (Page DL, Anderson TJ, eds). 1987;pp219-226, Churchill Livingstone, Edinburgh

• 9) Vos CB, Cleton-Jansen AM, Berx G, et al:E-cadherin inactivation in lobular carcinoma in situ of the breast:An early event in tumorigenesis. Br J Cancer 1997;76:1131-1133

• 10) Schrager CA. Schneider D, Gruener AC, et al:Clinical and pathological features of breast disease in Cowden's syndrome:An underrecognized syndrome with an increased risk of breast cancer. Hum Pathol 1998;29:47-53

• 11) Haagensen CD, Bodian C, Haagensen DE:Lobular Neoplasia (Lobular Carcinoma in situ) Breast Carcinoma:Risk and Detection. 1981;pp238-291, WB Saunders, Philadelphia

• 12) Rosen PP, Lieberman PH, Braun DW. et al:Lobular carcinoma of the breast:Detailed analysis of 99 patients with average follow-up of 24 years. Am J Surg Pathol 1978;2:225-251

• 13) Bradley SJ, Weaver DW, Bouwman DL:Alternatives in the surgical management of in situ breast cancer:A meta-analysis of outcome. Am Surg 1990;58:428-432

• 14) Gump FE, Kinne D, Schwartz GF:Current treatment for lobular carcinoma in situ. Ann Surg Oncol 1998;5:33-36

• 15) Nemoto T, Castillo N, Tsukada Y, et al:Lobular carcinoma in situ with microinvasion. J Surg Oncol 1998;67:41-46

• 16) Moran M, Haffty BG:Lobular carcinoma in situ as a component of breast cancer:The long-term outcome in patients treated with breast-conservation therapy. Int J Radiat Oncol Biol Phys 1998;40:353-358

• 17) Fisher B, Costantino JP, Wickerham DL, et al:Tamoxifen for prevention of breast cancer:Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Natl Cancer Inst 1998;90:1371-1388

• 18) Foote FW Jr, Stewart FW:A histologic classification of carcinoma in the breast. Surgery 1946;19:74-99

• 19) Rosen PP:Infiltrating lobular carcinoma. Diseases of the Breast (Harris JR, Lippman ME, Morrow M, et al, eds). 1996;pp420-424, Lippincott-Raven, Philadelphia

• 20) 坂元吾偉:浸潤性小葉癌. 乳腺腫瘍病理アトラス. 1995;pp58-63, 篠原出版, 東京

• 21) Toikkanen S, Pylkkanen L, Joensuu H:Invasive lobular carcinoma of the breast has better short-and long-term survival than invasive ductal carcinoma. Br J Cancer 1997;76:1234-1240

• 22) Rosen PP, Oberman HA:Carcinoma in fibroadenoma. Atlas of Tumor Pathology-Tumors of the Mammary Gland. 1993;pp106-107, AFIP, Washington DC

• 23) de las Morenas A, Crespo P, Moroz K, et al:Cytologic diagnosis of ductal versus lobular carcinoma of the breast. Acta Cytol 1995;39:865-869

• 24) Auger M, Huttner I:Fine-needle aspiration cytology of pleomorphic lobular carcinoma of the breast:Comparison with the classic type. Cancer 1997;81:29-32

• 25) Rosen PP, Oberman HA:Invasive carcinoma-invasive lobular carcinoma. Atlas of Tumor Pathology-Tumors of the Mammary Gland. 1993;pp168-175, AFIP, Washington DC

• 26) Oyama T, Kashiwabara K, Yoshimoto K, et al:Frequent overexpression of the cyclin D1 oncogene in invasive lobular carcinoma of the breast. Cancer Res 1998;58:2876-2880

• 27) De Leeuw WJ, Berx G, Vos CB, et al:Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol 1997;183:404-411

• 28) Lee JS, Grant CS, Donohue JH, et al:Arguments against routine contralateral mastectomy or undirected biopsy for invasive lobular breast cancer. Surgery 1995;118:640-647;discussion 647-648
  pubmed

• 29) Bouvet M, Ollila DW, Hunt KK, et al:Role of conservation therapy for invasive lobular carcinoma of the breast. Ann Surg Oncol 1997;4:650-654

• 30) Warneke J, Berger R, Johnson C, et al:Lumpectomy and radiation treatment for invasive lobular carcinoma of the breast. Am J Surg 1996;172:496-500

• 31) Holland PA, Shah A, Howell A. et al:Lobular carcinoma of the breast can be managed by breast-conserving therapy. Br J Surg 1995;82:1364-1366

P.269 掲載の参考文献

• 1) Montgomery H:Dermatology, vol 12. 1967;p1007, Harper & Row, New York

• 2) Velpeau A:A Treatise on the Diseases of the Breast and Mammary Region (Translated from the French by Mitchell Henry). 1856;p3, Sydenham Society, London

• 3) Paget Sir J:On disease of the mammary areola preceding cancer of the mammary gland. St Barth Hosp Reports 1874;10:86

• 4) 藤森正雄, 藤井孝尚:Paget癌. 現代産科婦人科学大系, 第11巻, 乳房とその疾患. 1972;pp281-288, 中山書店, 東京

• 5) Darier J:Sur une nouvelle forme de le psorospermose cutane:La maladie de Paget du mamelon. Compt Rend Soc de Biol Ser 1889;1:294

• 6) Jacobaeus HC:Paget's Disease unt sein Verhaltniss zum Milchdrusenkarzinom. Virchows Arch f Pathol Anat 1904;178:124-142

• 7) 太田正雄:ページェット氏病患者説明. 皮尿誌1913;12:1238

• 8) 安藤 亮:パーヂェット氏病ノ一例竝組織的検査ニ就テ. 皮尿誌1915;14:113-131

• 9) Haagensen CD:Paget's carcinoma of the breast. Diseases of the Breast, 3rd ed. 1986;pp758-781, WB Saunders, Philadelphia

• 10) 坂元吾偉, 菅野晴夫, 梶谷 環, ほか:乳房のPaget病. 癌の臨床1973;19:323-334

• 11) 日本乳癌学会(編):臨床・病理乳癌取扱い規約, 第13版. 1998;金原出版, 東京

• 12) 池出重雄:乳房Paget病の問題点. 皮膚臨床1970;12:261-280

• 13) Ashikari R, Park K, Huvos AG, et al:Page's disease of the breast. Cancer 1970;26:680-685

• 14) 加藤直人, 麻賀太郎, 吉田 明, ほか:乳腺部分切除(乳頭・乳輪および乳腺筒状切除)腋窩郭清を行い, 一期的に乳頭・乳輪の再建を行った乳腺Paget病の1例と乳腺Paget病に対する温存療法の可能性について. 乳癌の臨床1998;13:399-403

• 15) Pierce LJ, Haffty BG, Solin LJ, et al:The conservative management of Paget's disease of the breast with radiotherapy. Cancer 1997;80:1065-1072

P.275 掲載の参考文献

• 1) Lee BJ, Tannenbaum NE:Inflammatory carcinoma of the breast:A report of twenty-eight cases from the Breast Clinic of the Memorial Hospital. Surg Gynecol Obstet 1924;39:580-595

• 2) 冨永 健, 石井泰介:炎症性乳癌の悪性度. 乳癌の臨床1992;7:29-35

• 3) Kirby IB, Edward MC:The Breast, 2nd ed. 1998;pp1277-1298, WB Saunders, Philadelphia

• 4) Charpin C, Bounier P, Khouzami A, et al:Inflammatory breast carcinoma:An immunohistochemical study using monoclonal anti-pHER-2/neu, pS2, cathepsin, ER and PR. Anticancer Res 1992;12:591-598

• 5) Wakasugi H, Koyama K, Yoshimoto M, et al:Frequent development of murine T-cell lymphomas with TCR alpha/beta+, CD4-/8-phenotype after implantation of human inflammatory breast cancer cells in BALB/c nude mice. Jpn J Cancer Res 1995;86:1086-1096

• 6) Haagensen CD:Diseases of the Breast, 3rd ed. 1986;pp808-814, WB Saunders, Philadelphia

• 7) Treves N:The inoperability of inflammatory carcinoma of the breast. Surg Gynecol Obstet 1959;109:240-242

• 8) Parker LM, Sheldon TA, Cady B:Inflammatory breast cancer. Breast Diseases (Harris JR, ed). 1987;pp570-577, LB Lippincott, Philadelphia

• 9) Perez CA, Fields JN:Role of radiation therapy for locally advanced and inflammatory carcinoma of the breast. Oncology 1987;1:81-93

• 10) Fields JN, Kuske RR, Perez CA, et al:Prognostic factors in inflammatory breast cancer. Cancer 1989;63:1225-1232

• 11) Attia-Sobol J, Ferriere JP, Cure H, et al:Treatment results, survival and prognostic factors in 10g inflammatory breast cancers:Univariate and multivariate analysis. Eur J Cancer 1993;29A:1081-1088

• 12) Chevallier B, Bastit P, Graic Y, et al:The Centre H. Becquerel studies in inflammatory nonmetastatic breast cancer:Combined-modality approach in 178 patients. Br J Cancer 1993;67:594-601

• 13) Buzdar AU, Singletary SE, Booser DJ, et al:Combined modality treatment of stage III and inflammatory breast cancer. Surg Oncol Clin North Am 1995;4:715-734

• 14) Thomas F, Arriagada R, Spielmann M, et al:Pattern of failure in patients with inflammatory breast cancer treated by alternating radiotherapy and chemotherapy, Cancer 1995;76:2286-2296

• 15) Armstrong DK, Fetting JH, Davidson NE, et al:Sixteen-week dose-intense chemotherapy for inoperable, locally advanced breast cancer. Breast Cancer Res Treat 1993;28:277-284

• 16) Mourali N, Tabbane F, Muenz LR, et al:Ten-year results utilizing chemotherapy as primary treatment in nonmetastatic, rapidly progressing breast cancer. Cancer Invest 1993;11:363-370

• 17) Fein DA, Mendenhall NP, Marsh RD, et al:Results of multimodality therapy for inflammatory breast cancer:An analysis of clinical and treatment factors affecting outcome. Am Surg 1994;60:220-225

• 18) Noguchi S, Miyauchi K, Nishizawa Y, et al:Management of inflammatory carcinoma of the breast with combined modality therapy including intraarterial infusion chemotherapy as induction therapy. Cancer 1988;61:1483-1491

• 19) Maloisel F, Dufour P, Bergerat J, et al:Results of initial doxorubicin, 5-fluorouracil, and cyclophosphamide combination chemotherapy for inflammatory carcinoma of the breast. Cancer 1990;65:851-855

• 20) Morvan F, Espie M, Mignot L, et al:Fifteen years'follow-up for T4d (inflammatory) breast cancer patients. J Proc Am Soc Clin Oncol 1995;14:A265

• 21) Ellis DL, Teitelbaum SL:Inflammatory carcinoma of the breast:A pathologic definition. Cancer 1974;33:1045-1047

• 22) Lucas FV, Perez-Mesa C:Inflammatory carcinoma of the breast. Cancer 1978;41:1595-1605

• 23) Rouesse S, Sarrazin D, Mouriesse H, et al:Primary chemotherapy in the treatment of inflammatory breast carcinoma:A study of 230 cases from the Institute Gustave-Roussy. J Clin Oncol 1986;4:1765-1771

P.281 掲載の参考文献

• 1) Adair FE, Hermann JB:Primary lymphosarcoma of the breast. Surgery 1944;16:836

• 2) 堀内 篤:悪性リンパ腫. 内科学IV, 25. 血液疾患. 1992;pp1689-1697, 朝倉書店, 東京

• 3) 寺沢敏夫:第36回乳癌研究会アンケート調査. 日本癌治療学会誌1983;18:1226-1233

• 4) Wiseman C, Liao KT:Primary lymphoma of the breast. Cancer 1972;29:1705-1712

• 5) Mambo NC, Cho MB, Burke JS:Primary malignant lymphomas of the breast. Cancer 1977;39:2033-2040

• 6) Lamovec J, Jancar J:Primary malignant lymphoma of the breast:Lymphoma of the mucosa-associated lymphoid tissue. Cancer 1987;60:3033-3041

• 7) DeBlasio D, McCormick B, Straus D, et al:Definitive irradiation for localized non-Hodgkin's lymphoma of breast. Int J Radiat Oncol Biol Phys 1989;17:843-846

• 8) Hugh JC, Jackson FI, Hanson J, et al:Primary breast lymphoma:An immunohistologic study of 20 new cases. Cancer 1990;66:2602-2611

• 9) Smith MR, Brustein S, Straus DJ:Localized non-Hodgkin's lymphoma of the breast. Cancer 1987;59:351-354

• 10) Freeman C, Berg JW, Cutler SJ:Occurrence and prognosis of extranodal lymphomas. Cancer 1972;29:252-260

• 11) Dixon JM, Anderson TJ, Lamb J, et al:Fine needle aspiration cytology, in relationship to clinical examination and mammography in the diagnosis of a solid breast mass. Br J Surg 1984;71:593-596

• 12) Arber DA, Simpson JF, Weiss LM, et al:Non-Hodgkin's lymphoma involving the breast. Am J Surg Pathol 1994;18:288-295

• 13) Dixon JM, Lumsden AB, Krajewski A, et al:Primary lymphoma of the breast. Br J Surg 1987;74:214-216

• 14) Bobrow LG, Richards MA, Happerfield LC, et al:Breast lymphomas:A clinicopathologic review. Hum Pathol 1993;24:274-278

• 15) Brustein S, Filippa DA, Kimmel M, et al:Malignant lymphoma of the breast:A study of 53 patients. Ann Surg 1987;205:144-150

• 16) 松下啓二, 西牧敬二, 浦山弘明, ほか:乳腺原発悪性リンパ腫の1例. 日本臨床外科医学会雑誌1993;54:122-126

• 17) Harris NL, Jaffe ES, Stein H, et al:A revised European-American classification of lymphoid neoplasms:A proposal from the International Lymphoma Study Group. Blood 1994;84:1361-1392

• 18) Cohen PL, Brooks JJ:Lymphomas of the breast:A clinicopathologic and immunohistochemical study of primary and secondary cases. Cancer 1991;67:1359-1369

• 19) Liu FF, Clark RM:Primary lymphoma of the breast. Clin Radiol 1986;37:567-570

• 20) Schouten JT, Weese JL, Carbone PP:Lymphoma of the breast. Ann Surg 1981;194:749-753

• 21) Giardini R, Piccolo C, Rilke F:Primary non-Hodgkin's lymphomas of the female breast. Cancer 1992;69:725-735

• 22) Tanaka T, Hsueh CL, Hayashi K, et al:Primary malignant lymphoma of the breast:With a review of 73 cases among Japanese subjects. Acta Pathol Jpn 1984;34:361-373

• 23) 葵 景襄, 宮田 剛, 中野達也, ほか:男性乳腺原発悪性腫瘍の1例. 岩手県立病院医学会雑誌1985;25:125-127

• 24) 田中真理子, 中村仁信, 大井博道:乳房悪性リンパ腫の画像診断. 臨床放射線1985;30:117-119

• 25) Meyer JE. Kopans DB, Long JC:Mammographic appearance of malignant lymphoma of the breast. Radiology 1980;135:623-626

• 26) 平井恭二, 清水一雄, 内山喜一郎, ほか:乳腺に発生した悪性リンパ腫の2例-乳癌との比較検討を中心として. 日本臨床外科医学会雑誌1994;55:355-360

• 27) 勝木茂美, 唐木芳昭, 宗像周二, ほか:乳房に腫瘤を形成した悪性リンパ腫の1例-乳腺原発悪性リンパ腫本邦報告例121例についての集計. 日本臨床外科医学会雑誌1989;50:907-914

• 28) 白川 茂, 小林 透:悪性リンパ腫の治療方針. 医学のあゆみ1990;152:947-954

• 29) 下山正徳:非Hodgkinリンパ腫の治療図説臨床[癌]シリーズNo 17, 白血病・リンパ腫 (末舛恵一, 下山正徳, 編). 1987;pp139-149, メジカルビュー社, 東京

• 30) 下山正徳:成人T細胞白血病・リンパ腫(ATL). 臨床科学1989;25:1276-1282

• 31) 栗田宗次:腫瘤形成性白血病について. 臨床血液1982;23:433-440

• 32) Lin Y, Govindan R, Hess J:Malignant hematopoietic breast tumors. Am J Clin Pathol 1997;107:177-186

• 33) Gartenhaus WS, Mir R, Pliskin A, et al:Granulocytic sarcoma of breast:A leukemic bilateral metachronous presentation and literature review. Med Pediatr Oncol 1985;13:22-29

• 34) 内田立身, 西原利男:骨髄芽細胞腫(緑色腫). 別冊日本臨牀, 血液症候群III. 1998;pp180-182, 日本臨牀社, 大阪

P.298 掲載の参考文献

• 1) Bland KI, Copeland EM III (eds):The Breast. 1991, WB Saunders, Philadelphia

• 2) Donegan WL, Spratt JS(eds):Cancer of the Breast, 4th ed. 1995, WB Saunders, Philadelphia

• 3) Harris JR, Lippman ME, Morrow M, et al (eds):Diseases of the Breast. 1996, Lippincott-Raven, Philadelphia, New York

• 4) 泉雄 勝, 妹尾恒明(編):乳腺疾患, 第2版. 1993, 金原出版, 東京

• 5) 渡辺弘(監), 福田護(編):乳房温存療法のすべて. 1994, メジカルビュー社, 東京

• 6) 霞富士雄, 大川智彦, 坂元吾偉(編):乳房温存療法. 1994, 医学書院, 東京

• 7) 児玉 宏:胸筋温存乳癌根治手術. 1988, 金芳堂, 京都

• 8) 児玉 宏:乳癌の手術I, 乳房温存療法. 1998, 金芳堂, 京都

• 9) 幕内雅敏(監), 霞富士雄(編):乳腺外科の要点と盲点. 1998, 文光堂, 東京

• 10) 霞富士雄, 植野 映(編):乳癌の手術, 改訂第2版. 1998, 南江堂, 東京

• 11) 霞富士雄:乳癌手術アトラス. 1998, 医学書院, 東京

P.307 掲載の参考文献

• 1) Honig SF:Treatment of metastatic disease. Hormonal therapy and chemotherapy. Diseases ofthe Breast (Harris JR, Lippman ME, Morrow M, et al, eds). 1996;pp669-734, Lippincott-Raven, Philadelphia

• 2) Early Breast Cancer Trialists' Collaborative Group:Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31, 000 recurrences and 24, 000 deaths among 75, 000 women. Lancet 1992;339:1-15, 71-85

• 3) Early Breast Cancer Trialists' Collaborative Group:Tamoxifen for early breast cancer:An overview of the randomised trials. Lancet 1998;351:1451-1467

• 4) Fisher B, Costantino JP, Redmond CK, et al:Endometrial cancer in tamoxifen-treated breast cancer patients:Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP)B-14. J Natl Cancer Inst 1994;86:527-537

• 5) Fisher B, Costantino JP, Wickerham L, et al:Tamoxifen for prevention of breast cancer:Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998;9(1):1371-1388

• 6) Noguchi S, Koyama H, Kasugai T, et al:A case-control study on risk factors for local recurrences or distant metastases in breast cancer patients treated with breast-conserving surgery. Oncology 1997;54:468-474
  pubmed

• 7) Dalberg K, Johansson H, Johansson U, et al:A randomized trial of long term adjuvant tamoxifen plus postoperative radiation therapy versus radiation therapy alone for patients with early stage breast carcinoma treated with breast-conserving surgery. Cancer 1998;82:2204-2211

• 8) Stenbygaard LE, Herrstedt J, Thomsen JF, et al:Toremifene and tamoxifen in advanced breast cancer:A double-blind cross-over trial. Breast Cancer Res Treat 1993;25:57-63
  pubmed

• 9) Howell A, DeFriend D, Robertson J:Response to a specific antioestrogen (ICI182780) in tamoxifen-resistant breast cancer. Lancet 1995;345:29-30

• 10) O'Regan RM, Cisneros A, England GM, et al:Effects of the antiestrogens tamoxifen, toremifene, and ICI 182, 780 on endometrial cancer growth. J Natl Cancer Inst 1998;90:1552-1558

• 11) Taylor CW, Green S, Dalton WS, et al:Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer:An intergroup study. J Clin Oncol 1998;16:994-999

• 12) Kaufmann M:Luteinizing hormone-releasing hormone analogues in early breast cancer:Updated status of ongoing clinical trials. Br J Cancer 1998;78:9-11

• 13) Iveson TJ, Smith IE, Ahern J, et al:Phase I study of the oral nonsteroidal aromatase inhibitor CGS20267 in postmenopausal patients with advanced breast cancer. Cancer Res 1993;53:266-270

• 14) Dowsett M, Stein RC, Coombes RC:Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients. J Steroid Biochem Mol Biol 1992;43:155-159
  pubmed

• 15) Lonning PE:Aromatase inhibitors and their future role in post-menopausal women with early breast cancer. Br J Cancer 1998;78:12-15

• 16) Van Veelen H, Williemse PHB, Tjabbes T, et al:Oral high-dose medroxyprogesterone acetate versus tamoxifen:A randomized crossover trial in postmenopausal patients with advanced breast cancer. Cancer 1986;58:7-13

• 17) Oikawa T, Hiragun A, Yoshida Y, et al:Angiogenic activity of rat mammary carcinomas induced by 7, 12-dimethylbenz[α]anthracene and its inhibition by medroxyprogesterone acetate:Possible involvement of antiangiogenic action of medroxyprogesterone acetate in its tumor growth inhibition. Cancer Lett 1988;43:85-92

• 18) Abe O, Asaishi K, Izuo M, et al:Effects of medroxyprogesterone acetate therapy and its influence on blood coagulation and the fibrinolytic system. Surg Today 1995;25:701-710

• 19) 厚生省薬務局安全課:乳癌, 子宮体癌患者における高用量酢酸メドロキシプロゲステロン投与中の血栓症の発現. 医薬品研究1992;23:664-671

• 20) Goldhirsch A, Glick JH, Gelber RD, et al:Meeting highlights International consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 1998;90:1601-1608

• 21) Goldhirsch A, Wood WC, Senn HJ, et al:Meeting highlights:International consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 1995;87:1441-1445

• 22) 日本医薬情報センター(編):日本医薬品集, 1997年10月版. 1997, 薬業時報社, 東京

• 23) The Australian and New Zealand Breast Cancer Trials Group:A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. J Clin Oncol 1986;4:186-193

• 24) Mouridsen HT, Ellemann K, Mattsson W, et al:Therapeutic effect of tamoxifen versus tamoxifen combined with medroxyprogesterone acetate in advanced breast cancer in postmenopausal women. Cancer Treat Rep 1979;63:171-175

• 25) Boccardo F, Rubagotti A, Perrotta A, et al:Ovarian ablation versus goserelin with or without tamoxifen in premenopausal patients with advanced breast cancer:Results of a multicenter Italian study. Ann Oncol 1994;5:337-342
  pubmed

• 26) Jonat W, Kaufmann M, Blamey RW, et al:A randomized study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre-and perimenopausal patients with advanced breast cancer. Eur J Cancer 1995;31A:137-142
  pubmed

• 27) Tominaga T, Abe O, Oshima A, et al:Comparison of chemotherapy with or without medroxyprogesterone acetate for advanced or recurrent breast cancer. Eur J Cancer 1994;30A:959-964

• 28) 小山博記, 西沢征夫, 野口眞三郎, ほか:進行, 再発乳癌に対するsecond line treatmentとしての5'DFUR・MPA併用療法の効果. 日本癌治療学会誌1990;25:655-661

• 29) International Breast Cancer Study Group:Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. J Clin Oncol 1997;15:1385-1394

• 30) Fisher B, Dignam J, DeCillis A, et al:The worth of chemotherapy and tamoxifen (TAM) over TAM alone in node-negative patients with estrogen-receptor (ER) positive invasive breast cancer (BC). Proc Am Soc Clin Oncol 1997;16:1

• 31) Katzenellenbogen BS, Montano MM, Ekena K, et al:Antiestrogens:Mechanism of action and resistance in breast cancer. Breast Cancer Res Treat 1997;44:23-34

P.323 掲載の参考文献

• 1) Fisher B:The evolution of paradigms for the management of breast cancer:A personal perspective. Cancer Res 1992;52:2371-2383

• 2) Hortobagyi GN:Treatment of breast cancer. N Engl Med 1998;339:974-984

• 3) Cooper RG:Combination chemotherapy in hormone resistant breast cancer. Proc Am Assoc Cancer Res 1969;10:15

• 4) Nemoto T, Horton J, Simon R, et al:Comparison of four-combination chemotherapy programs in metastatic breast cancer:Comparison of multiple drug therapy with cytoxan, 5-FU and prednisone versus cytoxan and adriamycin, versus cytoxan, 5-FU and adriamycin, versus cytoxan, 5-FU and prednisone alternating with cytoxan and adriamycin. Cancer 1982;49:1988-1993

• 5) Tranum BL, McDonald B, Thigpen T, et al:Adriamycin combinations in advanced breast cancer. A Southwest Oncology Group Study. Cancer 1982;49:835-839

• 6) Cocconi G, Bisagni G, Bacchi M, et al:Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma:A prospective randomized trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 1991;9:664-669

• 7) Cortes JE, Pazdur R:Docetaxel. J Clin Oncol 1995;13:2643-2655

• 8) D'Andrea GM, Seidman AD:Docetaxel and paclitaxel in breast cancer therapy:Present status and future prospects. Semin Oncol 1997;24(4 suppl 13):S13-27-S13-44

• 9) Zujewski J, Nelson A, Abrams J:Much ado about not. . . enough data:High-dose chemotherapy with autologous stem cell rescue for breast cancer. J Natl Cancer Inst 1998;90:200-209
  pubmed

• 10) Hortobagyi GN:Drug therapy:Treatment of breast cancer. N Engl Med 1998;339:974-984

• 11) Hortobagyi GN, Singletary SE, McNees MD:Treatment of locally advanced and inflammatory breast cancer. Diseases of the Breast (Harris JR, Lippman ME, Morrow M, eds). 1996;pp 585-600, Lippincott-Raven, Philadelphia

• 12) Fisher B, Bryant J, Wolmark N, et al:Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;1612672-2685

• 13) 渡辺 亨, 勝俣範之, 奈良林至, ほか:乳癌の治療. 臨床腫瘍学, 第2版. 1998;pp1019-1056, 癌と化学療法社, 東京

• 14) Clark GM:Prognostic and predictive factors. Diseases of the Breast (Harris JR, Lippman ME, Morrow M, eds). 1996;pp461-486, Lippincott-Raven, Philadelphia

• 15) Fisher B, Fisher ER, Redmond C:Ten-year results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trial evaluating the use of L-phenylalanine mustard (LPAM) in the management of primary breast cancer. J Clin Oncol 1986;4:929-941

• 16) Bonadonna G, Valagussa P, Moliterni A, et al:Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer:The results of 20 years of follow-up. N Engl J Med 1995;332:901-906

• 17) Early Breast Cancer Trialists' Collaborative Group:Polychemotherapy for early breast cancer:An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998;352:930-942

• 18) Goldhirsch A, Glick JH, Gelber RD, et al:Meeting highlights:International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst 1998;90:1601-1608

• 19) Budman DR, Berry DA, Cirrincione CT, et al:Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 1998;90:1205-1211

• 20) Wood WC, Budman DR, Korzun AH, et al:Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994;330:1253-1259

• 21) Tsuda H, Akiyama F, Kurosumi M, et al:Establishment of histological criteria for high-risk node-negative breast carcinoma for a multiinstitutional randomized clinical trial of adjuvant therapy. Japan National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) Pathology Section, Jpn J Clin Oncol 1998;28:486-491

• 22) Watanabe T:Phase III randomized comparison of postoperative adjuvant chemotherapy with 2-year oral uracil/tegafur versus 6-cycle cyclophosphamide/methotrexate/5-fluorouracil in highrisk node-negative breast cancer patients. Cancer Chemother. Pharmacol 1998;42 (suppl):S68-S70

• 23) Watanabe T:Phase III randomized comparison of postoperative adjuvant chemotherapy with 2-year oral UFT (uracil/tegafur)versus six-cycle CMF (cyclophosphamide/methotrexate/5-fluorouracil) in high-risk node-negative breast cancer patients. Jpn J Clin Oncol 1998;28:77-80

• 24) Yamamoto N, Katsumata N, Watanabe T, et al:Clinical characteristics of patients with metastatic breast cancer with complete remission following systemic treatment. Jpn J Clin Oncol 1998;28:368-373

• 25) Greenberg PA, Hortobagyi GN, Smith TL, et al:Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996;14:2197-2205

• 26) Yamamoto N, Watanabe T, Katsumata N, et al:Construction and validation of a practical prognostic index for patients with metastatic breast cancer. J Clin Oncol 1998;16:2401-2408

• 27) Tranum B, Hoogstraten B, Kennedy A, et al:Adriamycin in combination for the treatment of breast cancer:A Southwest Oncology Group study. Cancer 1978;41:2078-2083

• 28) A'Hern RP, Smith IE, Ebbs SR:Chemotherapy and survival in advanced breast cancer:The inclusion of doxorubicin in Cooper type regimens. Br J Cancer 1993;67:801-805

• 29) Singal PK, Iliskovic N:Current concepts:Doxorubicin-induced cardiomyopathy. N Engl J Med 1998;339:900-905

• 30) Glaholm J, Mort C, Ashley S, et al:Duration of chemotherapy in advanced breast carcinoma. Lancet 1990;335:1033
  pubmed

• 31) Harris AL, Cantwell BM, Carmichael J, et al:Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer. Lancet 1990;335:186-190

• 32) Muss HB, Case LD, Richards F 2d, et al:Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. N Engl J Med 1991;325:1342-1348

• 33) Plotkin D, Ray M:Intermittent versus continuous chemotherapy for breast cancer. N Engl J Med 988;318:1467-1468

• 34) Coates A, Gebski V, Bishop JF, et al:Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med 1987;317:1490-1495

• 35) Dieras V, Barthier S, Beuzeboc P, et al:Phase II study of taxotere (T) in combination with doxorubicin (A) as 1st line chemotherapy (CT) of metastatic breast cancer (MBC). Breast Cancer Res Treat 1998;50:262

• 36) Sledge WJ, Neuberg D, Ingle J, et al:Phase III trial of doxorubicin (A) vs. paclitaxel (T) vs. doxorubicin+paclitaxel (A+T) as first-line therapy for metastatic breast cancer (MBC):An intergroup trial. Proc Am Soc Clin Oncol (abstr#2) 1997;16:1a

• 37) Kumar N:Taxol-induced polymerization of purified tubulin. Mechanism of action. J Biol Chem 1981;256:10435-10441

• 38) Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al:European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer:High-dose versus low-dose and long versus short infusion. J Clin Oncol 1994;12:2654-2666

• 39) Nabholtz JM, Gelmon K, Bontenbal M, et al:Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996;14:1858-1867

• 40) Berry D, Duggan D, Henderson IC, et al:Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer-Results from calgb 9342. Proc Am Soc Clin Oncol (abstr#388) 1998;17:101a

• 41) Abrams JS, Vena DA, Baltz J, et al:Paclitaxel activity in heavily pretreated breast cancer:A National Cancer Institute Treatment Referral Center trial J Clin Oncol 1995;13:2056-2065

• 42) Fountzilas G, Athanassiades A, Giannakakis T, et al:A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines, Eur J Cancer 1996;32A:47-51

• 43) Gianni L, Munzone E, Capri G, et al:Paclitaxel in metastatic breast cancer:A trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 1995;87:1169-1175

• 44) Seidman AD, Tiersten A, Hudis C, et al:Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer. J Clin Oncol 1995;13:2575-2581

• 45) Seidman AD, Reichman BS, Crown JP, et al:Paclitaxel as second and subsequent therapy for metastatic breast cancer:Activity independent of prior anthracycline response. J Clin Oncol 1995;13:1152-1159

• 46) Bishop JF, Dewar J, Toner G, et al:A randomized study of paclitaxel versus cyclophosphamide/ methotrexate/5-fluorouracil/prednisone in previously untreated patients with advanced breast cancer:Preliminary results. Taxol Investigational Trials Group, Australia/New Zealand. Semin Oncol 1997;24 (5 suppl 17):S17-5-S17-9

• 47) Bishop JF, Dewar J, Tattersall MHN, et al:Taxol (paclitaxel) alone is equivalent to CMFP combination chemotherapy as frontline treatment in metastatic breast cancer. Proc Am Soc Clin Oncol (abstr#538) 1997;16:153a

• 48) Trudeau ME, Eisenhauer EA, Higgins BP, et al:Docetaxel in patients with metastatic breast cancer:A phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 1996;14:422-428

• 49) Chevallier B, Fumoleau P, Kerbrat P, et al:Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer:A phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 1995;13:314-322

• 50) Hudis CA, Seidman AD, Crown JP, et al:Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1996;14:58-65

• 51) Ravdin PM, Burris HA 3rd, Cook G, et al:Phase II trial ofdocetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995;13:2879-2885

• 52) Valero V, Holmes FA, Walters RS, et al:Phase II trial of docetaxel:A new, highly efrective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995;13:2886-2894

• 53) Adachi I, Watanabe T, Takashima S, et al:A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer. Br J Cancer 1996;73:210-216
  pubmed

• 54) Bruno R, Hille D, Riva A, et al:Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998;16:187-196

• 55) Ravdin P, Valero V, Nabholts J-M:Efficacy of a 5-day corticosteroid premedication in amelio-rating Taxotere induced fluid retention. Proc Am Soc Clin Oncol (abstr#124) 1996;15:115

• 56) Piccart MJ, Klijn J, Paridaens R, et al:Corticosteroids significantly delay the onset of docetaxel-induced fluid retention:Final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol 1997;15:3149-3155

• 57) Nabholtz JM, Thuerlimann B, Bezwoda WR, et al:Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer. Oncology 1997;11 (8 suppl 8):25-30

• 58) Ando M, Watanabe T, Sasaki Y, et al:Aphase I trial of docetaxel and 5-day continuous infusion of 5-fluorouracil in patients with advanced or recurrent breast cancer. Br J Cancer 1998;77:1937-1943

• 59) Peters WP:High-dose chemotherapy with autologous bone marrow transplantation for the treatment of breast cancer. Important Advance in Oncology 1995 (Devita VTJ, Hellman S, Rosenberg SA, eds). 1995;pp215-230, JB Lippincott, Philadelphia

• 60) Bezwoda L, Seymour L, Dansey RD:High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer:A randomized trial. J Clin Oncol 1995;13:2483-2489

P.337 掲載の参考文献

• 1) Fletcher GH:History of irradiation in the primary management of apparently regional confined breast cancer. Int J Radiat Oncol Biol Phys 1985;11:2133-2142

• 2) Jacobson JA, Danforth DN, Cowan KH, et al:Ten-year results of a comparison ofconservation with mastectomy in the treatment of stage I and II breast cancer. N Engl J Med 1995;332:907-911

• 3) Fisher B, Anderson S, Redmond CK, et al:Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1995;333:1456-1461

• 4) Sarrazin D, Arriagada R, Contesso G, et al:Ten-year results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancer. Radiother Oncol 1989;14:177-184

• 5) Veronesi U, Banfi A, Salvadori B, et al:Breast conservation in the treatment of choice in small breast cancer:Long-term results of a randomized trial. Eur J Cancer 1990;26:668-670

• 6) NIH consensus conference:Treatment of early-stage breast cancer. JAMA 1991;265:391-395

• 7) Ries L:NCI surveillance program. J Natl Cancer Inst 1995;871339

• 8) Gage I, Recht A, Gelman R, et al:Long-term outcome following breast-conserving surgery and radiation therapy. Int J Radiat Oncol Biol Phys 1995;33:245-251

• 9) Sondik EJ:Reanalyses of NSABP studies. J Natl Cancer Inst 1994;86:655
  pubmed

• 10) Veronesi U, Luini A, Vecchio MD, et al:Radiotherapy after breast-preserving surgery in women With localized Cancer Of the breast. n Engl Med 1993;328:1587-1591

• 11) 野口眞一郎, 小山博記, 児玉 宏, ほか:早期乳癌953例に対する乳房温存療法の治療成績. 乳癌の臨床1994;9:565-572

• 12) 妹尾恒明:Quality of lifeとその評価法の概説. 乳癌の臨床1990;5:169-172

• 13) Sanger CK, Reznikofr M:A comparison of the psychological effects of breast-saving procedures with the modified radical mastectomy. Cancer 1981;48:2341-2346

• 14) Bartelink H, van Dam F, van Dongen J:Psychological effects of breast conserving therapy in comparison with radical mastectomy. Int J Radiat Oncol, Biol Phys 1985;11:38-385

• 15) Haagensen CD:Diseases of the Breast, 3rd ed. 1986, WB Saunders, Philadelphia

• 16) Thomas F, Arriagada R, Mouriesse H, et al:Radical radiotherapy alone in non-operable breast cancer:The major impact of tumor size and histological grade on prognosis. Radiother Oncol 1988;13:267-276

• 17) Martijin H, Caspers RJL, Welvaart K, et al:Locally advanced breast cancer:Radiotherapy alone versus surgery and radiotherapy. Radiother Oncol 1989;16:23-29

• 18) Ahern V, Barraclough B, Bosch C, et al:Locally advanced breast cancer:Defining an optimum treatment regimen. Int J Radiat Oncol, Biol Phys 1994;28:867-875

• 19) Lena MD, Varini M, Zucali R, et al:Multimodal treatment for locally advanced breast cancer:Results of chemotherapy-radiotherapy versus chemotherapy-surgery. Cancer Clin Trials 1981;4:229-236

• 20) Perloff M, Lesnick GJ, Korzun A, et al:Combination chemotherapy with mastectomy or radiotherapy for stage III breast carcinoma:A cancer and leukemia group B study. J Clin Oncol 1988;6:261-269
  pubmed

• 21) Touboul E, Buffat L, Lefranc JP, et al:Possibility of conservative local treatment after combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer. Int J Radiat Oncol Biol Phys 1996;34:1019-1028

• 22) Paterson R, Russel MH:Clinical trials in malignant disease. Part III-Breast cancer:Evaluation of post-operative radiotherapy. J Fac Radiol 1959;10:175-180

• 23) Palmer MK, Ribeiro CG:Thirty four years follow up of patients with breast cancer in clinical trial of postoperative radiotherapy. Br Med J 1985;291:1088-1091

• 24) Hamilton T, Langlands AO, Prescott RJ:The treatment of operable breast:A clinical trial in the South-East region of Scotland. Br J Surg 1974;61:758-761

• 25) Kaae S:Does simple mastectomy following by irradiation offer survival comparable to radical procedures? Int J Radiat Oncol Biol Phys 1977;2:1163-1166

• 26) Host H, Brennhovd IO, Loeb M:Postoperative radiotherapy in breast cancer:Long-term results from the Oslo study. Int J Radiat Oncol Biol Phys 1986;12:727-732

• 27) Fisher B, Redmond C, Fisher ER, et al:Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 1985;312:674-681
  pubmed

• 28) Rutqvist LE, Cedermark B, Glas U, et al:Radiotherapy, chemotherapy, and tamoxifen as adjuncts to surgery in early breast cancer:A summary of three randomized trials. Int J Radiat Oncol Biol Phys 1989;16:629-639

• 29) Edland RW:Does adjuvant radiotherapy have a role in the postmastectomy management of patients with operable breast cancer-revisited. Int J Radiat Oncol Biol Phys 1988;15:519-535

• 30) Abdel-Wahab M, Wolfson A, Raub W, et al:The importance of postoperative radiation therapy in multimodality management of locally advanced breast cancer:A phase II trial of neoadjuvant MVC, surgery, and radiation. Int J Radiat Oncol Biol Phys 1998;40:875-880

• 31) Greim KL, Henderson IC, Gelman R, et al:The 5-year results of a randomized trial of adjuvant radiation therapy after chemotherapy in breast cancer patients treated with mastectomy. J Clin Oncol 1987;5:1546-1555

• 32) Overgaard M, Christensen JJ, Johansen H, et al:Evaluation of radiotherapy in high-risk breast cancer patients:Report from the Danish breast cancer cooperative group (DBCG 82) trial. Int J Radiat Oncol Biol Phys 1990;19:1121-1124

• 33) Chu FCH, Lin FJ, Kim JH, et al:Locally recurrent carcinoma of the breast. Cancer 1976;37:2677-2681

• 34) Chen KK, Montague ED, Oswald MJ:Results of irradiation in the treatment of locoregional breast cancer recurrence. Cancer 1985;56:1269-1273

• 35) Patanaphan V, Salazar OM, Poussin-Rosillo H:Prognosticators in recurrent breast cancer:A 15-year experience with irradiation. Cancer 1984;54:228-234

• 36) Tukada Y, Fouad A, Pickren JW, et al:Central nervous system metastasis from breast carcinoma:Autopsy study. Cancer 1983;52:2349-2354

• 37) 宮岡和子, 小川一誠, 堀越 昇, ほか:乳癌の脳転移. 癌と化学療法1986;13:2370-2375

• 38) Flowers A, Levin VA:Management of brain metastases from breast carcinoma. Oncology 1993;7:21-26

• 39) Smalley SR, Schray MF, Laws ER, et al:Adjuvant radiation therapy after surgical resection of solitary brain metastasis:Association with pattern of failure and survival Int J Radiat Oncol Biol Phys 1987;13:1611-1616

• 40) Noordijk EM, Vecht CJ, Haaxma-Reiche H, et al:The choice of treatment of single brain metastasis should be based on extracranial tumor activity. Int J Radiat Oncol Biol, Phys 1994;29:711-717

• 41) Gelber RD, Larson M, Borgelt BB, et al:Equivalence of radiation schedules for the palliative treatment of brain metastases in patients with favorable prognosis. Cancer 1981;48:1749-1753

• 42) Egawa S, Tukiyama I, Akine Y, et al:Radiotherapy of brain metastases. Int J Radiat Oncol Biol Phys 1986;12:1621-1625

• 43) 大川智彦, 喜多みどり, 西島博司, ほか:転移性脳腫瘍に対する放射線治療の臨床的検討. 癌の臨床1988;34:1139-1146

• 44) 園尾博司:乳癌の骨転移. 骨転移-病態・診断・治療(大森弘之, 監). 1995;pp229-238, 金芳堂, 東京

• 45) Allen KL, Johnson TW, Hibbs GC, et al:Effective bone palliation as related to various treatment regimens. Cancer 1976;37:984-987

• 46) Garmatis CJ, Chu FCH:The effectiveness of radiation in the treatment of bone metastases from breast cancer. Radiology 1978;126:235-237

• 47) Tong D, Gillick L, Hendrickson FR:The palliation of symptomatic osseous metastases:Final results of the study by the Radiation Therapy Oncology Group. Cancer 1982;50:893-899

• 48) Okawa T, Kita M, Goto M, et al:Randomized prospective clinical study of small, large and twice-a-day fraction radiotherapy for painful bone metastases. Radiother Oncol 1988;13:99-104

• 49) Arcangeri G, Micheli A, Giannarelli D, et al:The responsiveness of bone metastases to radiotherapy:The effect of site, histology and radiation dose on pain relief. Radiother Oncol 1989;14:95-101

• 50) 山田省吾, 高井良尋, 根本健二, ほか:乳癌骨転移に対する放射線療法の検討. 癌の臨床 1982;28:111-115

• 51) Lingos T, Recht A, Vincini F, et al:Radiation pneumonitis in breast cancer treated with conservative surgery and radiation therapy. Int J Radiat Oncol Biol Phys 1991;21:355-360

• 52) Arriagada R, Mouriesse H, Rezvani A, et al:Radiotherapy alone in breast cancer:Analysis of tumor and lymph node radiation doses and treatment-related complications. Radiother Oncol 1993;27:1-6
  pubmed

• 53) Danofr BF, Pajak TF, Solin LJ, et al:Excisional biopsy, axillary node dissection and definitive radiotherapy for stage I and II breast cancer. Int J Radiat Oncol Biol Phys 1985;11:479-483

• 54) Durand JC, Poljicak M, Lefranc JP, et al:Wide excision of the tumor, axillary dissection, and postoperative radiotherapy as treatment of small breast cancers. Cancer 1984;53:2439-2443

• 55) Rutqvist LE, Liedberg A, Hammar N, et al:Myocardial infarction among women with early-stage breast cancer treated with conservative surgery and breast irradiation. Int J Radiat Oncol Biol Phys 1998;40:359-363

• 56) Zucali R, Merson M, Placucci M, et al:Soft tissue sarcoma ofthe breast after conservative surgery and irradiation for early mammary cancer. Radiother Oncol 1994;30:271-273

VI その他

P.350 掲載の参考文献

• 1) Ota J, Horino T, Taguchi T, et al:Mass screening for breast cancer:Comparison of the clinical stages and prognosis of breast cancer detected by mass screening and in out-patient clinics. Jpn J Cancer Res 1989;80:1028-1034

• 2) Kuroishi T, Tominaga S, Taguchi T, et al:The effect of mass screening for breast cancer:Results of a multivariate analysis. Jpn J Cancer Res 1991;82:27-32

• 3) Ohuchi N, Yoshida K, Kimura M, et al:Improved detection rate of early breast cancer in mass screening combined with mammography. Jpn J Cancer Res 1993;84:807-812

• 4) Ohuchi N, Yoshida K, Kimura M, et al:Comparison of false negative rates among breast cancer screening modalities with or without mammography:Miyagi trial. Jpn J Cancer Res 1995;861 501-506
  pubmed

• 5) 大内憲明, 遠藤登喜子, 辻 一郎, ほか:マンモグラフィー導入による乳がん検診の精度管理の確立に関する研究(7-8). 厚生省がん研究助成金による研究報告, 平成8年度, 1997;pp101-106, 国立がんセンター, 東京

• 6) 大内憲明, 森本忠興, 大貫幸二, ほか:乳がん検診の有効性評価に関する研究. がん検診の有効性評価に関する研究班報告書. 1998;pp173-216, 日本公衆衛生協会, 東京

• 7) 堀田勝平:マンモグラフィ導入乳癌検診に向けての撮影装置, 線量, 画質の実態調査. 厚生省がん研究助成金による「マンモグラフィ導入による乳がん検診の精度管理に関する研究」, 平成7年度研究報告. 1996;pp62-67

• 8) 東田善治, 今村恵子, 秋山芳久, ほか:乳房撮影装置のQC/QAに関する調査研究:精度管理システムの構築. マンモグラフィを導入した乳がん検診の実施体制についての調査研究報告書 (主任研究者, 大内憲明). 1998;pp8-10, 日本公衆衛生協会, 東京

• 9) Kanemura S, Tsuji I, Ohuchi N, et al:A case control study on the effectiveness of breast cancer screening by clinical breast examination in Japan. Jpn J Cancer Res 1999;90:607-613

• 10) Kerlikowske K, Grady D, Rubin SM, et al:Efficacy of screening mammography:A meta-analysis. JAMA 1995;273:149-1541

• 11) Kopans DB:Mammography screening and the controversy concerning women aged 40 to 49. Radiol Clin North Am 1995;33:1273-1290

• 12) Bjurstam N, Bjorneld L, Duffy SW, et al:The Gothensburg breast screening trial:First results on mortality, incidence, and mode of detection for women ages 39-49 years at randomization. Cancer 1997;80:2091-2099

• 13) 大内憲明, 大貫幸二, 吉田弘一, ほか:早期乳癌比率と中間期乳癌発生率からみたマンモグラフィ併用検診の適正な検診間隔. 日本乳癌検診学会誌1996;5:245-248

• 14) 大貫幸二, 辻 一郎, 大内憲明, ほか:乳癌検診の費用効果分析. 日本乳癌検診学会誌1997;6:145-151

• 15) 飯沼 武, 松本 徹, 館野之男:乳房撮影を用いる乳癌検診の利益と被曝によるリスク. 日本乳癌検診学会誌1994;3:227-236

• 16) 大内憲明, 遠藤登喜子, 辻 一郎, ほか:マンモグラフィ導入による乳癌検診の問題点と対策:厚生省班研究報告. 日本乳癌検診学会誌1997;6:137-143

• 17) 大内憲明, 遠藤登喜子, 東田善治, ほか:総括研究報告. マンモグラフィを導入した乳がん検診の実施体制についての調査研究報告書(主任研究者, 大内憲明). 1998;pp3-7, 日本公衆衛生協会, 東京

• 18) 遠藤登喜子, 岩瀬拓士, 大貫幸二, ほか:マンモグラム読影医師の実態調査報告. 日本乳癌検診学会誌1998;7:257-266

• 19) 今村恵子, 福田 護, ほか:マンモグラフィの精度管理のためのファントム画像データベース:第2報. 日本乳癌検診学会誌1998;7:103-112

• 20) 遠藤登喜子, 岩瀬拓士, 大貫幸二, ほか:乳房画像診断用語集Breast imaging lexicon. 日本乳癌検診学会誌1998;7:63-70

• 21) 遠藤登喜子, 岩瀬拓士, 大貫幸二, ほか:検診マンモグラムにおける読影所見の記載方法Reporting system. 日本乳癌検診学会誌1998;7:71-73

P.365 掲載の参考文献

• 1) 加藤順三:乳癌とエストロゲン受容体. 内分泌・糖尿病科1996;3:333-342

• 2) 加藤順三:子宮体癌と乳癌の共通点と相違点-主として内分泌学的観点から. 産科と婦人科 1994;61:1233-1240

• 3) Gustafsson JA:Estrogen receptor β-getting into the action? Nat Med 1997;3:493-494

• 4) Harlap S:The benefits and risks of hormone replacement therapy:An epidemiologic overview. Am J Obstet Gynecol 1992;166:1986-1992
  pubmed

• 5) Pasqualini JR, Schatz B, Varin C, et al:Recent data on estrogen sulfatases activities in human breast cancer. J Steroid Biochem Mol Biol 1992;41:323-329

• 6) Bulun SB, Simpson ER:Regulation of aromatase expression in human tissues. Breast Cancer Res Treat 1994;30:19-29

• 7) Harada N, Utumi T, Takagi Y:Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis. Proc Natl Acad Sci USA 1993;90:11312-11316

• 8) Labrie F, Simard L, Luu-The V, et al:Molecular biology of androgen formation and degradation in peripheral intracrine tissue. The 11th International Symposium of the Journal of Steroid Biochemistry and Molecular Biology, Tirol, Austria. 1993;p16

• 9) Burke W, Daly M, Garber J, et al:Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. JAMA 1997;277:997-1003

• 10) van der Burg V, de Groot RP, Isbrucker I, et al:Direct stimulation by estrogen of growth factor signal transduction pathways in human breast cancer cells. J Steroid Biochem Mol Biol 1992;43 (1-3):111-115

• 11) 西澤恭子:ホルモン依存性癌. 最新内科学大系, 第16巻, 性腺疾患(井村裕夫ほか, 編). 1993;pp303-312, 中山書店, 東京

• 12) 加藤順三:脳内ステロイドホルモン受容体研究-1976-1995年-取り込み機構・受容体分子・遺伝子発現. 日本内分泌学会雑誌1996;72:27-70

• 13) 坂元秀樹, 大谷 香, 太田ヒロオ, ほか:c-erbB2の子宮癌in vitro増殖における意義の検討. 日本産科婦人科学会雑誌1992;44:800-804

• 14) Sato B, Kouhara H, Koga M, et al:Androgen-induced growth factor and its receptor:Demonstration of the androgen-induced autocrine loop in mouse mammary carcinoma cells. J Steroid Biochem Mol Biol 1993;47 (1-6):91-98

• 15) Sato T, Akiyama F, Sakamoto G, et al:Accumulation of genetic alterations and progression of primary breast cancer. Cancer Res 1991;51:5794-5799

• 16) Imamura T, Arima T, Kato H, et al:Chromosomal deletions and K-ras gene mutations in human endometrial carcinomas. Int J Cancer 1992;51:47-52

• 17) Fujimoto I, Shimizu Y, Hirai Y, et al:Studies on ras oncogene activation in endometrial carcinoma. Gynecol Oncol 1993;48:196-202

• 18) McGuire WL, Chamness GC, Fuqua SAW:Estrogen receptor variants in clinical breast cancer. Mol Endocrinol 1991;5:1571-1577

• 19) Ehrlich CE, Young PCM, Stehman FB, et al:Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. Am J Obstet Gynecol 1988;158:796-807

• 20) Matsumoto K, Kitamura Y, Sugano H:Hormone receptors and Japanese breast cancer. Acta Pathol Jpn 1982;32 (suppl 1):145-154

• 21) 加藤順三:人子宮体癌の受容体分析-ホルモン依存性本態の解明. 日本産科婦人科学会雑誌 1978;30:818-827

• 22) 加藤順三:性ホルモン受容体-基礎と臨床. 日本産科婦人科学会雑誌1994;46:647-658

• 23) Creasman WT, Soper JT, McCarty KS Sr, et al:Influence of cytoplasmic steroid receptor content on prognosis of early endometrial carcinoma. Am J Obstet Gynecol 1985;151:922-932

• 24) Gusberg SB:Virulence factors in endometrial cancer. Cancer 1993;71 (suppl 4):1464-1466

• 25) Kato J:Endometrial cancer:Epidemiology, early diagnosis, steroid hormone receptor status and an aberrant gene expression of the receptors. Women's Health Today (Popkins DR, Peddle I, eds). 1994;pp119-128, The Parthenon Publishing Group, New York, London

• 26) Kleine MT, Maier T, Geyer H, et al:Estrogen and progesterone receptors in endometrial cancer and their prognostic relevance. Gynecol Oncol 1990;38:59-65

• 27) Creasman WT:Prognostic significance of hormone in endometrial cancer. Cancer 1993;71 (suppl 4):1467-1470

• 28) Evans RM:The steroid and thyroid hormone receptor superfamily. Science 1988;240:889-895

• 29) Murphy LC:Mechanism associated the progression of breast cancer from hormone dependence to independence. Peacoller Found J 1995;2:6-16

• 30) Katzenellenbogen BS, Korach KS:A new actor in the estrogen receptor drama-enter ERβ. Endocrinology 1997;138:861-862

• 31) Castles CG, Fuqua AWS, Klotz DM, et al:Expression of a constitutive active estrogen receptor variant in the estrogen receptor-negative BT-20 human breast cancer cell line. Cancer Res 1993;53:5934-5939

• 32) Desai AJ, Luqmani YA, Walters JE, et al:Presence of exon 5-deleted oestrogen receptor in human breast cancer:Functional analysis and clinical significance. Br J Cancer 1997;75:1173-1184

• 33) Murphy LC, Dotzlaw H, Leygue E, et al:The pathophysiological role of estrogen receptor variants in human breast cancer. J Steroid Biochem Mol Biol 1998;65(1-6):175-180

• 34) Leygue E, Huang A, Murphy LC, et al:Prevalence of estrogen receptor variant messenger RNAs in human breast cancer. Cancer Res 1996;56:4324-4327

• 35) Fuqua SAW, Fitzgerald SD, Allred DC, et al:Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors. Cancer Res 1992;52:483-486

• 36) Pfeffer U, Fecarotta E, Arena G, et al:Alternatively splicing of the estrogcn receptor primary transcript normally occurs in estrogen receptor positive tissues and cell lines. J Steroid Biochem Mol Biol 1996;56:99-105

• 37) Fuqua SAW, Fitzgerald SD, Chamness GC, et al:Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res 1991;51:105-109

• 38) Huang A, Pettigrew N, Watson P:Immunohistochemical assay for oestrogen receptors in paraffin wax sections of breast carcinoma using a new monoclonal antibody. J Pathol 1996;180:223-227

• 39) Huang A, Leygue E, Snell L, et al:Expression of estrogen receptor variants mRNAs and determination of estrogen status in human breast cancer. Am J Pathol 1997;150:1827-1833

• 40) Hirata S, Yamada-Mouri N, Nara M, et al:Presence of alternatively spliced estrogen receptor mRNA variants in the human endometrial cancer. Endocr J 1995;42:289-293

• 41) Tremblay GB, Tremblay A, Copeland NG, et al:Cloning, chromosomal localization, and functional analysis of the uterine estrogen receptorβ. Mol Endocrinol 1997;11:353-365

• 42) Kuiper GG, Gustafsson JA:The novel estrogen receptor β subtype:Potential role in the celland promoter-specific actions of estrogens and anti-estrogens. FEBS Lett 1997;410:87-90

• 43) Mosselman S, Polman J, Dijkema R:ERβ:Identification and characterization of a novel human estrogen receptor. FEBS Lett 1996;392:49-53

• 44) Dotzlaw H, Leygue E, Watson P, et al:Expression of estrogen receptor β in human breast tumors. J Clin Endocrinol Metab 1998;82:2371-2374

• 45) Vladusic EA, Hornby AE, Guerra-Vladusic FK, et al:Expression of estrogen receptor β messenger RNA variant in breast cancer. Cancer Res 1998;58:210-2144

• 46) Colditz GA, Hankinson SE, Hunter DJ, et al:The use of estrogens and progestins and the risk of breast cancer in postm enopausal women. N Engl J Med 1995;332:1589-1593

• 47) 加藤順三, 岩本 豪, 平田修司:加齢に伴う卵巣機能低下症. ホルモンと臨床1996;44:1075-1084

• 48) Collaborative Group on Hormonal Factors in Breast Cancer:Breast cancer and hormone replacement therapy:Collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 1997;350:1047-1059

• 49) Willis DB:Does estrogen replacement therapy reduce the risk of fatal breast cancer in postmenopausal women. Maturitas 1997;27:105-108

• 50) Wentz AC:Management of the menopause. Novak's Textbook of Gynecology, 11th ed. 1988;pp397-442, Williams & Wilkins, Baltimore

• 51) Collaborative Group on Hormonal Factors in Breast Cancer:Breast cancer and hormonal contraceptives:Collaborative reanalysis of individual data on 53, 297 women with breast cancer and 100, 239 women without breast cancer from 54 epidemiological studies. Lancet 1996;347:1713-1727

• 52) 泉雄 勝:乳癌のホルモン療法, 最近の話題. 日本内分泌学会雑誌1992;68:538-549

P.373 掲載の参考文献

• 1) Kasumi F:Innovations and research progress of the department of breast surgery, Cancer Institute Hospital, Tokyo, Japan. Breast Cancer 1998;5:326-330

• 2) Bostwick III J:Plastic and Reconstructive Breast Surgery, vol II. 1990;pp758-881, Quality Medical Publishing, St Louis

• 3) 岩平佳子, 丸山 優:乳房再建術・その2-Tissue expanderによる. 臨床科学1992;28:535-539

• 4) 岩平佳子, 塙 陽子, 矢高森人, ほか:Double-pedicle TRAM flapを用いた乳房再建術. 日本形成外科学会会誌1997;17:640-650

• 5) 酒井成身:陥没乳頭の手術. 手術1996;50:1667-1676